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The opportunistic pathogen Pseudomonas aeruginosa causes severe disease in people 
with compromised immune systems or co-morbidities such as diabetes or cystic fibrosis. 
Since even intense antibiotic regimens are often ineffective, there is a great need to better 
understand P. aeruginosa infection biology. Our first research goal was to elucidate the 
role of glutathione (GSH) biosynthesis for P. aeruginosa during infection. GSH is a major 
cellular antioxidant that is important for protection from oxidative stress. We found that 
GSH biosynthesis provides protection against some antimicrobials, such as bleach and 
ciprofloxacin. We also discovered that GSH biosynthesis provides a modest fitness benefit 
to P. aeruginosa in a mouse model of acute pneumonia, but not in chronic wound, 
abscess, and burn wound mouse models. Our second research goal was to characterize 
the transcriptomic and proteomic signatures of growth rate in P. aeruginosa. Growth rate 
has significant impacts on cellular physiology, from cell size to stress tolerance. We 
cultured P. aeruginosa at four different growth rates using a chemostat, and quantified 
mRNA and protein abundances using RNA-seq and proteomics mass spectrometry, 
respectively. We observed modest correlations between mRNA and protein expression. 
We also discovered that there was greater variation in mRNA expression compared to 
protein expression, and that mRNA expression was more strongly affected by changes in 
growth rate. We calculated protein-to-mRNA ratios, or conversion factors, which could be 
used to more accurately predict protein abundance from RNA-seq data. The information 









Infections caused by the bacterium Pseudomonas aeruginosa are a major public health 
threat (1). This Gram-negative bacterium is most commonly isolated from areas 
associated with human activity, including contaminated soil, water, and hospital fomites 
(1-3). As an opportunistic pathogen, it primarily infects people with compromised immune 
systems and underlying comorbidities, particularly cystic fibrosis and diabetes (1). It can 
infect multiple body sites, including the skin and soft tissues, lungs, eyes, bloodstream, 
and urinary tract (1). A large number of in vitro and in vivo models are used to study P. 
aeruginosa virulence, and it is clear that the traits required for P. aeruginosa fitness in 
these models can vary (4-6). This may be due to differences in nutrient availability, innate 
immune defenses, or other environmental factors, such as oxygen tension or pH. P. 
aeruginosa is naturally tolerant to many conventional disinfectants and antibiotics, and 
there is increasing global incidence of P. aeruginosa strains with multi-drug resistance 
traits (7-9). There is currently no vaccine against P. aeruginosa, and therapeutic regimens 
used to treat this bacterium are often ineffective. For these reasons, there is an urgent 
need to better understand P. aeruginosa infection biology. This thesis is focused on 
                                               
1 Parts of this subsection were adapted from the following reference: Michie, K.L., et al., The Role 
of Pseudomonas aeruginosa Glutathione Biosynthesis in Lung and Soft Tissue Infection. Infection 
and Immunity, 2020.  IAI.00116-20; DOI: 10.1128/IAI.00116-20. Copyright © American Society for 
Microbiology 2020. Reused with permission. I was the primary author of this work. 
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elucidating the mechanisms of P. aeruginosa pathophysiology in human infections. 
Chapter 1, the introduction, details the basic microbiology of P. aeruginosa. This includes: 
a discussion of the types of infections caused by P. aeruginosa; antimicrobial resistance; 
virulence factors; quorum sensing and social behaviors; and laboratory models used to 
study P. aeruginosa pathophysiology. Chapter 2 presents research on the role of 
glutathione biosynthesis in P. aeruginosa mammalian infection. In Chapter 3 the gene and 
protein expression signatures correlated with growth rate in P. aeruginosa are 
characterized. Finally, Chapter 4 summarizes the main conclusions of this body of work 
and explores potential future directions   
1.2 P. aeruginosa microbiology 
P. aeruginosa is a Gram-negative, flagellated, rod-shaped member of the Proteobacteria 
phylum (10). P. aeruginosa has a relatively large genome, on average about 6 Mbp, and 
the core genome is highly conserved between strains (11). This large genome equips P. 
aeruginosa with a broad, versatile repertoire of physiological functions and traits. For 
example, P. aeruginosa can thrive in a wide variety of habitats. It is an environmental 
organism that is ubiquitously found in soil, water, and on man-made surfaces, particuarly 
environments associated with human contact (2, 3). This is especially problematic in 
hospital settings, where P. aeruginosa can readily colonize sinks, faucets, doorknobs, and 
surgical or respiratory equipment (12-15). P. aeruginosa is a facultative anaerobe, 
meaning that it grows most efficiently in the presence of oxygen, but it can survive without 
oxygen by switching to a fermentative metabolism using alternative electron acceptors 
such as nitrate (10). P. aeruginosa has extensive metabolic capabilities, and can 
catabolize a wide variety of organic compounds (16). These features allow P. aeruginosa 
to grow even in harsh, nutrient-poor environments.    
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1.3 Types of infections caused by P. aeruginosa 
1.3.1 P. aeruginosa epidemiology 
P. aeruginosa is a leading cause of morbidity and mortality worldwide. The Centers for 
Disease Control and Prevention (CDC) classify P. aeruginosa as a “threat level serious 
pathogen”, their 2nd highest threat ranking (17). In 2019, the CDC reported 32,600 
nosocomial (hospital-acquired) P. aeruginosa infections and 2,700 deaths (17). P. 
aeruginosa infections also place a tremendous burden on the healthcare system; in 2019 
the CDC estimated that $767 million was spent on healthcare costs associated with these 
infections in the US (17).  P. aeruginosa is an opportunistic pathogen, meaning that it 
rarely causes disease in healthy individuals, but can cause serious or lethal disease in 
individuals with compromised immune defenses. Common comorbidities associated with 
P. aeruginosa infection include type 2 diabetes, cystic fibrosis, cancer, HIV, burns, surgical 
wounds, catheterization, and ventilation (1, 10, 15). P. aeruginosa is a major cause of 
nosocomial infections because hospitalized patients are often susceptible to P. 
aeruginosa, it easily colonizes hospital surfaces (12-15), and it can transfer person-to-
person. As described in further detail in section 1.4, P. aeruginosa infections are difficult 
to treat due to its high innate tolerance to disinfectants and antibiotics. Its ability to grow 
in diverse, harsh environments, coupled with its arsenal of virulence factors, allow P. 
aeruginosa to cause disease in many different infection sites throughout the body. These 
sites include the skin and soft tissues, lungs, eyes, ears, bloodstream, and urinary tract 
(1, 10, 15). This work focuses on P. aeruginosa infections of the lungs and soft tissues.  
1.3.2 Chronic wound infections 
Approximately 6.5 million Americans suffer from chronic wound infections annually (18). 
These painful infections are associated with steep declines in patient quality of life, and 
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severe cases can lead to permanent tissue damage, amputation, and death (18). Chronic 
wound infections are defined as soft-tissue injuries that fail to proceed through normal 
reparative stages and have not healed by 3 months (18, 19). Chronic wounds may stay 
open and infected for months, years, or may never heal (18, 19). They are characterized 
by prolonged, uncontrolled inflammatory responses, leading to tissue damage and 
weakened immune defenses (18, 19). Common causes of chronic wound infections 
include pressure ulcers, surgical incisions, and acute trauma (19). Chronic wounds are 
rare in normally healthy people, but are linked to comorbidities such as diabetes, obesity, 
and old age (18, 19). Type 2 diabetics are 3 times more likely to develop chronic wound 
infections and are 28 times more likely to undergo lower extremity amputation due to these 
infections than non-diabetics (18, 20) Caring for chronic wounds is also very expensive; 
the associated healthcare costs total $25 billion in the US annually (18). Unfortunately, the 
incidence of these infections is only projected to increase as the number of Americans 
with comorbidities such as diabetes and obesity continue to rise (18).  
Chronic wounds are typically colonized by complex polymicrobial communities that are 
often comprised of more than 10 bacterial species (21-27). Although highly diverse, 
particular species often predominate, and several species have been correlated with 
prolonged wound healing and tolerance to antimicrobial treatment. Although the data 
varies based on the type of wound and the methodology, large-scale studies indicate that 
P. aeruginosa is present in 15% to 80% of human chronic wounds (21, 22, 24, 25). There 
is also evidence that its prevalence may be even higher, since P. aeruginosa occupies 
deeper sites within the wound, hampering identification (28). P. aeruginosa is believed to 
exacerbate the prolonged inflammatory response and contribute to tissue destruction.  
Compared to chronic wounds that do not contain P. aeruginosa, chronic wounds that 
contain P. aeruginosa are more severe, heal at a slower rate, and are more likely to result 
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in amputation or death. P. aeruginosa is also very difficult to eradicate from chronic 
wounds, owing to its ability to form multi-species biofilms in the wound (29-31). For these 
reasons, there is strong evidence that P. aeruginosa is a key mediator of chronic wound 
persistence (24, 32, 33).   
1.3.3 Burn wound infections 
Like chronic wounds, burn wounds also affect the skin and soft tissues. However, unlike 
chronic wounds, burns are acute pathologies. Burns are associated with rapid, 
uncontrolled inflammatory responses and oxidative damage. Following a thermal injury, 
there is a heightened inflammatory response that leads to production of reactive oxygen 
species (ROS) and reactive nitrogen species (RNS); activation of phagocytic cells; lipid 
peroxidation; tissue thrombosis, ischemia and reperfusion; and activation of tissue 
proteases (34-36). These effects cause both local and systemic acute tissue damage, and 
can lead to tissue necrosis, shock, multiple organ failure, and death (34, 35).  
P. aeruginosa is a pathogen of major importance in burn wounds. P. aeruginosa spread 
is particularly threatening in hospital burn care centers, where it can be introduced into 
burn wounds through exposure from contaminated stool, water, and hospital surfaces (10, 
15, 37). It is one of the most common organisms isolated from infected burned patients 
(10, 15, 37). Various burn wound centers have reported P. aeruginosa incidence in about 
15%-30% of patients (38-40). Unlike chronic wound infections, P. aeruginosa can kill 
infected burn wound patients in days or weeks. As an opportunistic pathogen, P. 
aeruginosa proliferates rapidly in immunologically weakened burned tissue, and can 
contribute to tissue destruction, sepsis, and death. Burn wounds containing P. aeruginosa 
are associated with a sharply increased risk of tissue damage and mortality, with reported 
fatality rates of 50% to 60% (10, 15, 41).  
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1.3.4 Cystic fibrosis lung infections 
An estimated 30,000 people in the US (70,000 globally) have cystic fibrosis (CF), a life-
long genetic disease caused by mutations in the cystic fibrosis transmembrane 
conductance regulator (CFTR) gene (1, 42). The CFTR protein regulates chloride 
transport across epithelial cell membranes. Defective CFTR function results in the build-
up of extremely thick, viscous mucus in the airways. Normally, the cilia lining the 
respiratory tract beat rhythmically to shuttle mucus out of the lungs, helping to trap and 
expel invading bacteria. However, in CF, the cilia are unable to clear the thick mucus, 
which significantly weakens the lung’s innate immune defenses. The relatively static 
environment, impaired immune defences, and the rich nutritional density of the mucus (43) 
makes the CF lung highly susceptible to bacterial infection (42). Similarly to chronic wound 
infections, CF lungs are also chronically infected by complex, polymicrobial communities 
of bacteria and other microbes (42). CF patients suffer from chronic bacterial lung 
infections and from recurring flare-ups, despite intensive therapeutic regimens. Bacterial 
colonization in turn triggers sustained inflammation and immune cell infiltration into the 
lung, further contributing to lung tissue damage (42). While therapeutic advances over the 
past several decades have dramatically improved CF patient quality of life and lifespan, 
there is still no cure for CF (44).  
 In CF patients, P. aeruginosa is considered the major cause of morbidity and mortality 
(44). Early in life, people with CF tend to be initially colonized with other bacterial species, 
such as Staphylococcus aureus, but as they grow into adulthood, P. aeruginosa tends to 
predominate (45, 46). About 80% of all adult CF patients will become persistently infected 
with P. aeruginosa (44, 45, 47). Acquisition of P. aeruginosa is associated with an 
accelerated decline in lung function and worsened survival (47-49). Over the course of 
prolonged CF lung infection, P. aeruginosa undergoes several important adaptations that 
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enhance its ability to evade the immune system and resist antibiotics (50, 51). One of the 
most striking adaptations is the mucoidy phenotype, in which P. aeruginosa overproduces 
the extracellular exopolysaccharide alginate. Alginate overproduction makes colonies 
slick and sticky, which may impede phagocytosis or antibody binding (10, 52, 53). Other 
evolutionary adaptations include modulation of immunostimulatory components and 
virulence factors (as described in section 1.5), such as loss of O-antigen subunits from 
lipopolysaccharide (LPS) (54-56), downregulation of pili and flagella, upregulation of multi-
drug efflux pumps (50, 51), hypermutator mutations in DNA repair machinery (57), and 
loss of quorum sensing (58, 59). 
1.3.5 Acute pneumonia 
Pneumonia is defined as infection and inflammation of the lungs, and can be accompanied 
by coughing, fever, chills, build-up of fluid and pus, difficulty breathing, and ultimately 
death (60). Hospital-acquired pneumonia (HAP) occurs when someone receiving hospital 
treatment for a different reason acquires pneumonia during their hospital stay (60-62). 
HAP places a tremendous burden on the healthcare system by contributing to lengthened 
hospital stays, poorer clinical outcomes, and increased healthcare costs. It is also the most 
life-threatening type of nosocomial infection (61, 62).  HAP typically affects individuals that 
are already sick, and risk factors include age (over 65), cancer, and HIV. Patients on 
ventilators in intensive care units are at especially high risk of developing a specific type 
of HAP called ventilator-associated pneumonia (VAP) (60). 10%-20% of people on 
ventilators for 48 hours or longer develop VAP (62).  
P. aeruginosa is one of the leading causes of HAP, particularly VAP, and is found in 16-
30% of all HAP cases (61, 63, 64). HAP cases caused by P. aeruginosa typically require 
lengthier hospital stays and have a higher likelihood of death, with morality rates as high 
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as 70% (61, 63, 64). As described in section 1.3.1, P. aeruginosa is exceedingly difficult 
to control in a hospital setting because it can spread person-to-person and it readily 
colonizes hospital surfaces, including respiratory equipment. During acute lung infections, 
P. aeruginosa surface antigens such as LPS and flagella trigger a robust inflammatory 
response. This leads to recruitment of neutrophils and release of ROS, which also cause 
lung tissue damage (64). Furthermore, virulence factors, such as the T3SS (type III 
secretion system, described in section 1.5), allow P. aeruginosa to inject lung cells with 
toxins. These can disrupt the lung epithelial barrier and allow the bacteria to invade and 
become septic, which can lead to shock, multiple organ failure, and death (64). 
1.4 Antimicrobial resistance in P. aeruginosa  
Over the past few years, improvements in prevention strategies have helped reduce the 
yearly burden of antibiotic resistant infections. These strategies include improved hospital 
hygiene and sterilization practices, adoption of more careful antibiotic stewardship, and 
aggressive antibiotic resistant organism detection and response (17). However, the threat 
from antibiotic resistant infections remains very high. The CDC estimates that each year 
in the US there are over 2.8 million antibiotic-resistant infections and over 35,000 
associated deaths (17). The National Institutes of Health (NIH) names P. aeruginosa a 
member of the six ESKAPE pathogens, which are clinically relevant for their high 
virulence, transmissibility in hospital settings, and antibiotic resistance. The six ESKAPE 
pathogens are Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, 
Acinetobacter baumannii, P. aeruginosa, and Enterobacter spp. (65).  A major problem in 
common with all 4 types of P. aeruginosa infections discussed in section 1.3 (chronic 
wound, burn wound, CF lung infection, and acute pneumonia) is the difficulty in preventing 
and treating P. aeruginosa infections due to its high resistance to disinfectants and 
antibiotics. P. aeruginosa is a veritable Swiss Army Knife of antimicrobial resistance, 
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thanks to its relatively large genome and ability to gain new antibiotic resistance 
mechanisms. These resistance mechanisms can be classified into two categories: intrinsic 
or acquired.  
1.4.1 Intrinsic antibiotic resistance mechanisms 
Intrinsic antimicrobial resistance mechanisms are part of an organism’s innate ability to 
tolerate antimicrobials. These mechanisms are encoded in the organism’s genome, and 
are usually fundamental structural or physiological properties that provide protection 
against harmful substances (1, 66). P. aeruginosa has multiple mechanisms of intrinsic 
antimicrobial resistance that make it naturally highly tolerant to many common 
disinfectants and antibiotics. Many of these defense mechanisms likely evolved to protect 
P. aeruginosa from naturally occurring toxic compounds present in the environment or 
produced by competing environmental organisms (66, 67).   
One intrinsic resistance strategy is limiting the entry of antimicrobials. Hydrophilic 
antimicrobials can diffuse into the P. aeruginosa cell membrane through porins or non-
specific membrane channels. Therefore, reducing expression of these non-specific 
channels or porins, such as the OprD porin, limits entry of antimicrobials (1, 66, 68).  
Another strategy is export of antimicrobials. Multi-drug efflux pumps are membrane-
spanning protein complexes that pump harmful substances out of the cell (1, 66, 69). Multi-
drug efflux pumps can have broad specificity and be active against a range of chemically 
unrelated compounds, including multiple classes of antibiotics (1, 66, 69). P. aeruginosa 
encodes several different multi-drug efflux pumps, including MexAB-OprM, 
MexXY/OprM(OprA), MexCD-OprJ, and MexEF-OprN (1, 66, 69). A third mechanism of 
innate resistance is inactivating harmful compounds. For example, P. aeruginosa encodes 
an inducible β-lactamase (AmpC) that degrades aminopenicillins and most 
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cephalosporins (1, 57, 66). P. aeruginosa also produces a variety of proteins and 
metabolites for detoxifying ROS and RNS, such as glutathione, catalases, and superoxide 
dismutases (70, 71).   
1.4.2 Acquired antibiotic resistance mechanisms 
Acquired mechanisms involve mutations in intrinsic antibiotic resistance genes or 
acquisition of new antibiotic resistance genes via horizontal gene transfer (HGT) (1, 57). 
Unlike intrinsic antibiotic resistance mechanisms, acquired mechanisms have evolved and 
spread due to intense selection pressure from human antibiotic usage (1). Acquired 
resistance mechanisms are genetically stable and are passed onto progeny, which allows 
strains with acquired resistance mechanisms to proliferate and spread rapidly (1). The 
spread of multi-drug resistant (MDR) P. aeruginosa strains is a particularly serious 
problem in hospital settings, where patients are typically at higher risk for infection and 
MDR strains can spread person-to-person (1, 38, 39). P. aeruginosa strains are classified 
as multi-drug resistant (MDR) if they are resistant to 1 or more drugs in at least 3 antibiotic 
classes (17). Some strains of MDR P. aeruginosa are resistant to nearly all antibiotics, 
including carbapenems (17). 
One method of acquired resistance involves mutations in intrinsic antibiotic resistance 
regulatory mechanisms. Intrinsic resistance mechanisms are typically under the control of 
one or more regulatory systems; mutations in these systems can cause overexpression 
of resistance mechanisms, thereby increasing antibiotic resistance (1). For example, 
mutations in the negative regulators of AmpC or various multidrug efflux pumps results in 
enhanced antibiotic resistance in P. aeruginosa (1, 57, 69, 72). In the case of OprD, 
inactivating mutations reducing or eliminating the expression of OprD can enhance 
resistance (1, 68). Acquired antibiotic resistance mechanisms can also include mutation 
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in the drug target site. For instance, mutations in binding sites for the fluoroquinolone 
targets, DNA gyrase and topoisomerase IV, confers P. aeruginosa resistance to 
fluoroquinolones (57, 73).  
The second method of acquired antibiotic resistance is acquisition of new genes from 
different strains or species through HGT (57, 74). HGT can be accomplished through 
conjugation, transduction, or transformation, and may involve mobile genetic elements 
such as plasmids, integrons, or transposons (57, 74). Mobile genetic elements are easily 
shared between bacterial species, which can lead to rapid rises in antibiotic resistance 
(17). Reservoirs of mobile antibiotic resistance genes emerge from environments with 
heavy antibiotic usage, such as hospitals (75), industrial feedlots (76), fisheries (77), and 
areas with pharmaceutical industrial pollution (78). More than one antibiotic resistance 
gene may be present on a plasmid, enabling bacteria to become MDR upon acquisition 
(74). Some examples of antibiotic resistance genes acquired through HGT in P. 
aeruginosa include acquired extended-spectrum β-lactamases (7, 79), carbapenemases 
(79), aminoglycoside modifying enzymes (80), and 16s rRNA modifying enzymes (57, 81).  
1.5 P. aeruginosa virulence factors 
Virulence factors are commonly defined as physiological traits that aid an organism’s 
ability to cause disease (51, 82). Virulence factors may help a pathogen initially colonize 
the host, disseminate throughout the host, evade the immune response, replicate, or 
persist during infection (82). P. aeruginosa is equipped with a large, diverse set of both 
cell-associated and secreted virulence factors. Having an extensive selection of virulence 
factors allows P. aeruginosa to successfully colonize a wide variety of environmental 




P. aeruginosa secretes several extracellular proteases that digest complex proteins and 
peptides. These include elastase A (staphylolysin), elastase B, protease IV (lysyl 
endopeptidase), and alkaline protease (aeruginolysin). These proteases together can 
degrade important structural components of tissue, such as elastin, fibrin, collagen, and 
laminin, which causes tissue necrosis and hemorrhagic lesions (15, 83).   
Hemolysins 
Hemolysins are pore-forming toxins that solubilize lipids by disrupting phospholipid 
membranes. They are notable for their ability to lyse red blood cells. P. aeruginosa 
secretes several hemolysins, including phospholipases, lipases, and lecithinase. 
Phospholipase C hydrolyzes phospholipids such as phosphatidylcholine and 
sphingomyelin. It also degrades the phosphatidylcholine component of lecithin, which is a 
major component of lung surfactant, and has been shown to impair lung function during 
acute or chronic lung infections (15, 64, 84, 85).  
Rhamnolipids 
Rhamnolipids are biosurfactants that reduce liquid surface tension. Rhamnolipid 
production allows P. aeruginosa to swim across solid or semi-solid surfaces in coordinated 
groups through a process called swarming motility. Rhamnolipids are also cytotoxic to 
competing bacterial cells and eukaryotic host cells, and interfere with normal cilia function 





An extremely toxic compound secreted by P. aeruginosa is exotoxin A, which inhibits 
protein translation in eukaryotic host cells. Depending on the concentration, when injected 
into mammalian hosts it causes tissue necrosis, neutropenia, shock, and death (15, 90, 
91).  
Pyocyanin 
The pigment pyocyanin gives P. aeruginosa its distinctive blue-green color. Pyocyanin is 
a redox-active phenazine that generates toxic quantities of ROS that can kill other 
microbes and damage host cells. This mechanism is particularly potent in the lung where 
pyocyanin oxidizes glutathione (GSH), which is naturally present at high quantities, 
leading to ROS generation and lung damage (92-96).  
Siderophores 
Iron is an essential nutrient for most microorganisms, including P. aeruginosa. As a 
defense against invading microorganisms, hosts limit the availability of free iron in the 
body by sequestering it with iron-binding molecules, such as heme, transferrin, and 
lactoferrin. To obtain iron during infection, P. aeruginosa secretes two siderophores, 
pyochelin and pyoverdine. These are iron-chelating molecules that compete with host iron-
binding molecules to bind and transport iron into the cell. Siderophore production is 
essential in numerous models of P. aeruginosa infection. (97-99) 
Slime layer 
The outermost component of the P. aeruginosa cell is the slime layer. This sticky coating 
is composed of exopolysaccharides, nucleic acids, hyaluronic acid, lipids, and proteins. It 
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may help protect the cell from desiccation and phagocytosis and also may aid attachment 
and biofilm formation. Mucoid P. aeruginosa mutants from CF lung infections overproduce 
the exopolysaccharide alginate (15, 52, 53, 56). 
LPS  
The outer membrane of Gram-negative bacteria has two leaflets; the inner leaflet is 
composed of phospholipids, the outer leaflet is composed of LPS (also known as 
endotoxin). LPS consists of lipid A (the endotoxic portion), core polysaccharides, and outer 
O antigens. LPS provides the outer membrane with structural integrity and increases the 
negative charge. It is also highly immunogenic; purified LPS alone can induce systemic 
shock and death. P. aeruginosa can remodel the number and structure of its O antigens. 
Over the course of chronic CF lung infection, P. aeruginosa strains tend to reduce the 
number of O antigens (LPS rough phenotype) which may help it evade the host immune 
response (54-56).   
Flagella 
Flagella are long, whip-like extracellular structures that rotate rapidly like a propeller to 
allow microorganisms to swim. P. aeruginosa has a single, polar flagellum. In some acute 
infections, like burn wound infections, flagella are important for fitness as they aid in 
dissemination and chemotaxis. However, flagella are also highly immunogenic and can 
be recognized by phagocytes. In chronic infections, like CF lung infections, mutants 
frequently lose their flagella, which may aid in immune evasion (1, 4, 50, 51).  
Pili 
Type IV pili are hair-like cellular structures sprouting from the surface of the cell’s poles. 
Repeated extension and retraction of the pili, like a grappling hook, enables a form of 
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movement named twitching motility. Type IV pili may be useful to P. aeruginosa for 
exploring the environment, adhering to abiotic or biotic surfaces, and for biofilm formation. 
However, they are immunogenic and recognized by the immune system (56, 100, 101). 
Secretion systems 
P. aeruginosa encodes five different secretion systems (T1SS, T2SS, T3SS, T5SS, and 
T6SS), each with different structures and functions. These syringe-like cellular 
appendages, which are structurally similar to phage tails, are used to inject effector 
proteins into the extracellular environment or into the cytoplasm of bacteria or eukaryotic 
cells. Specifically, the T3SS and T6SS are capable of injecting effector toxins into 
eukaryotic host cells. Notably, the T3SS is an important fitness determinant for acute 
pneumonia infections, as it is used to disrupt lung epithelial tight junctions, allowing 
dissemination into the bloodstream (64, 102, 103). 
Biofilm formation 
P. aeruginosa exists in either a free-floating planktonic mode or a biofilm mode of growth, 
and there are major physiological differences between the two. A biofilm is like a “slime 
city” (104), where bacterial communities form sessile, aggregate-associated 
microcolonies covered in a protective coating of extracellular polymeric substances (EPS). 
The EPS is composed mainly of exopolysaccharides, extracellular DNA, proteins, and 
lipids. Bacteria growing in biofilms have significantly heightened resistance to ROS and 
phagocytosis, nutrient or oxygen limitation, and tolerance to antimicrobials (1, 64). Biofilms 
make it more difficult to eradicate P. aeruginosa from abiotic surfaces, such as surgical 
implants, catheters, and respirators (1). Biofilm formation is also an important component 
of chronic infections, such as chronic wound infections and CF lung infections (1, 31, 64). 
P. aeruginosa can form mixed-species polymicrobial biofilms with other microorganisms 
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in these infections, and such biofilms are more antibiotic resistant and virulent than single-
species P. aeruginosa biofilms (29, 30, 33, 105, 106).  
1.6 Quorum sensing and social behaviors2 
Once thought to be solitary, independent organisms, we now know that bacteria are highly 
social and are capable of coordinating complex behaviors as a community via cell–cell 
communication (107). Social behaviors are mainly driven by either competition or 
cooperation. Cooperation occurs when a behavior benefits another individual (108). 
Bacteria are most cooperative toward clonal (genetically identical) relatives; since clonal 
bacteria share identical genes, they have a collective motivation to enhance their 
population’s fitness (ability to survive and reproduce) by cooperating with each other (108). 
Social communication often regulates behaviors which are effective only at high cell 
density, such as the production and release of public goods. Public goods are extracellular 
products that can improve the fitness of neighboring bacteria, making them “social” traits 
(109). Examples include extracellular digestive proteases and siderophores. Social 
communication prevents inefficient public goods production at low population densities, 
when most secreted products would diffuse away rather than benefit the community (110).  
The best understood form of bacterial communication is quorum sensing. Quorum sensing 
is mediated by diffusible signal molecules known as autoinducers (111). The characteristic 
autoinducer for quorum sensing in Gram-negative bacteria, and in P. aeruginosa, is the 
acyl homoserine lactone, or AHL. AHLs freely diffuse out of and into cells and accumulate 
in proportion to cell density. After reaching a critical concentration, they bind to and 
                                               
2 Parts of this subsection were adapted from the following reference: Michie, K.L., et al., Bacterial 
tweets and podcasts# signaling# eavesdropping# microbialfightclub. Molecular and biochemical 
parasitology, 208(1), 41-48. DOI: 10.1016/j.molbiopara.2016.05.005. Copyright © Elsevier B.V 
2016. Reused with permission. I was the primary author of this work. 
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activate their cognate cytoplasmic receptors, causing a conformational change in the 
receptors that allows them to bind DNA and alter the transcription of target genes (111). 
Receptor-AHL activation also induces a positive feedback loop by increasing the 
transcription of AHL-synthesis genes, therefore resulting in rapid extracellular 
accumulation of AHL and a synchronized change in gene expression and behavior in the 
population. P. aeruginosa has three complex and interconnected quorum sensing 
systems: las, rhl, and pqs. (112, 113). 
In P. aeruginosa, many genes associated with virulence are under the control of quorum 
sensing, such as motility (114), biofilm formation (114), antibiotic resistance (115), stress 
responses (115), and virulence factor production (1, 113). Virulence factors controlled by 
quorum sensing include extracellular proteases (83, 116), pyocyanin (94), exotoxin A (90), 
rhamnolipids (86), siderophores (97), and T6SS (103). Because so many different 
virulence factors are regulated by quorum sensing, it is not surprising that quorum sensing 
deficient P. aeruginosa mutants are often severely attenuated in laboratory models of 
infection, including lung and soft tissue models (117-119). However, a notable exception 
is that in the late stages of CF lung infection, P. aeruginosa isolates often evolve 
inactivating mutations in quorum sensing genes (58, 59). Therapeutic interventions aimed 
at inhibiting quorum sensing are attractive avenues for investigation, and have shown 
some promise in laboratory models (120-122). One key advantage of quorum sensing 
inhibitors is that they are unlikely to drive selective pressure for resistance against them, 
because unlike conventional antibiotics, quorum sensing inhibitors do not kill or inhibit the 




1.7 Laboratory models of P. aeruginosa infection 
Since human experimentation is unethical, better understanding the infection biology of P. 
aeruginosa necessitates the use of laboratory models. There are a wide variety of 
commonly used P. aeruginosa laboratory models, from cell-free in vitro systems to large 
mammals. Every model has different advantages and disadvantages in terms of cost, 
ease of use, genetic tractability, ethical considerations, and which aspects of human 
infection biology are best recapitulated. While no model can perfectly represent a human 
infection, it is important to consider each model’s limitations, which aspects are biologically 
relevant, and how relevance can be improved.  
1.7.1 In vitro and ex vivo model systems 
Simple in vitro models using culture tubes and undefined complex media, such as LB 
broth, have been used to elucidate countless important discoveries about P. aeruginosa 
physiology. These systems are relatively inexpensive, easy to manipulate, and can be 
carried out on large scales. However, there are several drawbacks which may often be 
overlooked. Notably, the nutritional environment does not reflect a natural environment, 
there is no spatial structure, and P. aeruginosa grows to unrealistically high population 
densities. Some in vitro systems have attempted to better simulate the nutritional 
composition of human infection environments and introduce host factors. Synthetic cystic 
fibrosis sputum medium (SCFM) was designed to mimic the nutritional and physical 
properties of expectorated sputum from CF patients (43). Physiological parameters of P. 
aeruginosa, such as growth rate and gene expression, are similar in SCFM compared with 
expectorated human CF sputum. Importantly, SCFM has a similar viscosity to human 
sputum, which provides spatial structure (5, 43, 126). Likewise, a wound-like medium 
(WLM) was designed to mimic the nutritional environment of a human chronic wound (106, 
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127). P. aeruginosa can grow as a mixed-species biofilm in WLM, and in the presence of 
S. aureus, which clots blood, the WLM even forms spatially structured blood clots (106, 
127).  
Macrophages and neutrophils are important components of the innate immune defense 
against P. aeruginosa infections. Researchers wishing to study interactions between P. 
aeruginosa and phagocytes can use in vitro co-culture systems with these cell types. 
Neutrophils are short-lived and must be extracted from healthy human volunteers (128), 
while macrophages can either be freshly extracted or cultured from immortalized cell lines 
(129, 130). Alternatively, P. aeruginosa can be co-cultured with the amoeba Dictyostelium 
discoideum, a natural predator of P. aeruginosa. Interactions between P. aeruginosa and 
Dictyostelium replicate interactions with phagocytes, and are useful for high-throughput 
genetic screens of P. aeruginosa traits important for resisting phagocytosis and killing by 
phagocytic cells. It is also useful for screening host phagocyte genes that are important 
for resistance to P. aeruginosa infection. Compared to phagocytes, Dictyostelium is easier 
to grow and genetically manipulate (131-133).  
To study interactions between P. aeruginosa and particular tissue types, P. aeruginosa 
can be cultured with primary or immortalized cell lines. Primary cells are taken fresh from 
a living or recently deceased organism and cultured in vitro. Primary cells more closely 
retain the characteristics of intact tissue, but they have a limited lifespan outside the body, 
making them challenging to obtain and grow. Immortalized cell lines have undergone 
repeated passaging or genetic manipulation in order to allow them to replicate 
continuously in vitro. They are more convenient to use, more reproducible, and can also 
be further genetically manipulated to study host genes of interest. However, they often 
have significant genetic and physiological differences compared to primary cells or 
parental tissue (134, 135). Commonly used cell types include normal and CFTR knock-
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out ciliated lung epithelial cells (89, 136, 137),  corneal epithelial cells (138, 139), and skin 
fibroblasts or keratinocytes (140, 141). These in vitro co-culture systems are useful for 
studying mechanisms of P. aeruginosa tissue colonization, the impact of virulence factors 
on host cell survival, and host cell inflammatory responses to P. aeruginosa infection.   
Ex vivo models involve co-culturing P. aeruginosa in sections of whole organ tissue. Two 
major advantages of an ex vivo organ system are that the tissue slices retain their complex 
three-dimensional spatial structure, and it allows for cross-talk between all of the different 
cell types present in a whole organ. An ex vivo pig lung model uses pig lungs obtained 
from commercial butchers. Ex vivo pig lungs are physiologically similar to human lungs, 
are relatively inexpensive, and raise fewer ethical concerns, since the lungs from pigs 
raised for food are usually discarded (142, 143). Other similar models use rabbit or goat 
corneas sourced from butchers (144, 145). Organ sections can also be acquired from 
human donors, including corneas from cadavers (144) and excised skin leftover from 
surgical procedures (146).  
1.7.2 Plant and invertebrate model systems 
Plant and invertebrate laboratory models feature whole multicellular organisms with intact 
but rudimentary immune systems. They are relatively inexpensive, quick and easy to use, 
high-throughput, genetically tractable, and without ethical restrictions. Therefore, these 
systems can allow for larger sample sizes than what is feasible with mammalian models. 
Validating the usefulness of these models, there is strong overlap in the genes necessary 
for P. aeruginosa to cause disease in plants, invertebrates, and mammals. 
In nature, P. aeruginosa is known to colonize plants and is sometimes a plant pathogen 
(3, 147). Laboratory plant models of P. aeruginosa pathogenesis include the classic model 
organism Arabidopsis thaliana (103, 148-150), as well as mung bean (151), alfalfa (152), 
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and store-bought lettuce (149). An advantage of plant models is that they allow qualitative 
(plant growth, tissue damage) and quantitative (bacterial loads) measures of disease 
progression. These infections can also be relatively long-lived, for example up to 5 or 10 
days. Of these models, Arabidopsis is the most well characterized, but mung beans grow 
faster. Store-bought lettuce requires no growing time, but the infections are short (24hrs).  
There are several invertebrate laboratory models of P. aeruginosa infection, including the 
nematode Caenorhabditis elegans (148, 153-155), the fruit fly Drosophila melanogaster 
(30, 71, 156) and the greater wax moth Galleria mellonella (54, 157, 158). C. elegans is a 
soil organism that naturally feeds on bacteria. One advantage of the C. elegans model is 
that fluorescently tagged bacteria colonizing the gut can be easily imaged with fluorescent 
microscopy. However, the Drosophila immune system and tissue structure have more 
elements in common with mammals (159, 160). Greater wax moth larvae are relatively 
large (250mg) and can be easily seen without the aid of a microscope, making it easier to 
inject the bacteria, control bacterial inoculum sizes, and identify dead larvae. One 
limitation of all three invertebrate systems is that these hosts die very quickly from P. 
aeruginosa infection (usually 24-48hrs, but can survive up to 4 days).   
1.7.3 Vertebrate model systems 
Vertebrate model systems are more similar to humans in several important ways. For 
instance, they have similar organ and tissue structures and both innate and adaptive 
immunity is present. However, vertebrate model systems require strict ethical regulations, 
specialized facilities, personnel training, and are significantly more expensive. Popular 
models include zebrafish (Danio rerio) (54, 161), mice (Mus musculus) (148, 157, 162), 
rats (Rattus norvegicus) (163-167), and pigs (Sus scrofa domesticus) (168-171).  
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Zebrafish are non-mammalian vertebrate models with several useful characteristics. They 
reproduce quickly in large numbers, their genome is well characterized and relatively 
tractable, and many mutants are readily available. There are also fewer ethical restraints; 
experiments performed on zebrafish embryos under 5 days post-fertilization are legally 
considered in vitro experiments (54). Notably, zebrafish embryos are transparent, making 
it easy to visualize fluorescently labeled bacteria or host cell proteins in whole embryos 
using fluorescence microscopy (54, 161).  
Mice are the most widely used mammalian model of P. aeruginosa infection. Four of these 
infection models, the chronic wound (4, 29), abscess (172, 173), burn wound (4, 174), and 
acute pneumonia models (175, 176), are discussed in further detail in Chapter 2. 
Additional models include  keratitis (162, 177), intraperitoneal (178, 179), and foreign body 
surgical implant (180-182). The mouse genome is very well characterized, with many 
genetic tools, inbred mice and mutant mice available to researchers, such as  diabetic 
(183, 184), CF (169, 185), and immune-deficient mice (177, 186-189). This is a major 
advantage, since comorbidities and host genetics can significantly impact susceptibility to 
P. aeruginosa infection (187, 190-192). However, there are important physiological 
differences between mice and humans that are worth considering. For instance, there are 
species-specific differences in the sensitivity of toll-like receptor 4 (TLR4) to recognize 
different forms of LPS, with mouse TLR4 tending to be more promiscuous (192, 193). 
Another difference is that in humans, skin wounds heal primarily by granulation and re-
epithelialization, while in mice they heal primarily by contraction (194, 195). Third, since 
P. aeruginosa is an opportunistic pathogen, young and healthy immune-competent mice 
are generally resistant to P. aeruginosa infection. Consequently, mouse models often 
require high inoculating doses that likely do not recapitulate natural human routes of 
infection.  
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While rats are closely related to mice, rats are bigger, making it is easier to take multiple 
blood draws, work with small organs, perform delicate surgery, and monitor physiological 
parameters like pulse, temperature, and breathing rate. These characteristics may be 
desirable for certain infection models, such as ureter stent (165), orthopedic surgical 
wounds (167), inner ear (90) or septicemia (196). Compared to mice, rat physiology is 
better characterized and may be closer to humans in some respects (197, 198). However, 
rats can be more difficult to handle, are more expensive, require more space to house, 
and the available genomic resources are not yet as developed as they are for mice (198, 
199).  
The P. aeruginosa infection model that is the largest, and arguably the most similar to 
humans, is the pig. Humans are evolutionarily more closely related to pigs than to rats or 
mice, and pig anatomy, histology, and metabolism resembles that of humans (200). P. 
aeruginosa infection models include septic shock (170, 201), acute pneumonia (171, 202), 
and surgical wounds (203, 204). As previously discussed, CF mutant mice have been 
developed; however, how well they recapitulate the CF disease manifestations that occurs 
in humans is limited. For instance, it is difficult to establish a long-lasting chronic lung 
infection (205). CF pig models have been developed that more closely replicate the 
constellation of disease pathologies seen in human CF patients, including the 
characteristic inflammation, mucus buildup, and chronic bacterial infection. Studies using 
CF pigs have been used to identify novel therapeutic targets that weren’t apparent in 
mouse models (168, 169). However, maintaining and experimenting on laboratory pigs 
requires large and specialized housing facilities, equipment, and training. Genetic 
resources are also limited. Combined, laboratory experiments involving pig models are 
very expensive and only allow for small sample sizes.  
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THE ROLE OF PSEUDOMONAS AERUGINOSA GLUTATHIONE 
BIOSYNTHESIS IN LUNG AND SOFT TISSUE INFECTION3 
 
 
1.8 Background and significance 
To survive in both the environment and in the host, P. aeruginosa must cope with redox 
stress. Glutathione (GSH) is a major cellular regulator of redox homeostasis (206, 207). It 
is a low molecular weight thiol-containing tripeptide (L-γ-glutamyl-L-cysteinyl-glycine) that 
can function as a reversible reducing agent by either directly interacting with reactive 
oxygen (ROS) and nitrogen (RNS) species or indirectly by serving as an enzymatic 
cofactor (207, 208). GSH is produced by most Gram-negative bacteria, by a few Gram-
positive bacteria, and it is ubiquitous and essential in eukaryotic cells (206, 207, 209). 
Bacteria that do not biosynthesize GSH often produce functionally similar molecules, such 
as mycothiol or bacillithiol (210-212).  In addition to protection from oxidative and 
nitrosative stress, GSH is involved in many important cellular functions, such as 
detoxification of electrophilic compounds, lipid peroxides, toxic metabolites and 
xenobiotics; regulation of cellular osmolality and pH (206, 213); and metal homeostasis 
(206, 207).    
                                               
3 This chapter was adapted from the following reference: Michie, K.L., et al., The Role of 
Pseudomonas aeruginosa Glutathione Biosynthesis in Lung and Soft Tissue Infection. Infection 
and Immunity, 2020 IAI.00116-20; DOI: 10.1128/IAI.00116-20. Copyright © American Society for 
Microbiology 2020. Reused with permission. I was the primary author of this work. 
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In P. aeruginosa, genetic defects in GSH biosynthesis result in a myriad of altered 
phenotypes both in vitro and in vivo that suggest an important role during infection. GSH 
biosynthesis has been shown to affect quorum sensing (214), T3SS and T6SS (176), 
production of the secondary metabolites pyocyanin and pyoverdine (71, 215), motility (71, 
176, 215), biofilm formation (71, 176, 215), sensitivity to oxidative and nitrosative stress 
(71, 176, 215), and sensitivity to antibiotics (216, 217). GSH-deficient P. aeruginosa 
mutants have attenuated virulence in Drosophila (71) and C. elegans infection models 
(155), as well as a mouse model of acute pneumonia (176). Glutathione-deficient mutants 
in other bacterial species are also attenuated for virulence in mouse models of infection, 
including Salmonella enterica in an intraperitoneal model  (218), Listeria monocytogenes 
in an intravenous model (208), and Burkholderia pseudomallei in an acute pneumonia 
model (219).  
A large number of in vitro and in vivo models are used to study P. aeruginosa virulence, 
and it is clear that the traits required for P. aeruginosa fitness in these models can vary 
(4-6). This may be due to differences in nutrient availability, innate immune defenses, or 
other environmental factors, such as oxygen tension or pH. However, the role of GSH for 
P. aeruginosa pathogenesis in mammalian infection, particularly in different sites of 
infection, is still unclear. In this study, we first examined how GSH deficiency affects P. 
aeruginosa’s growth rate and susceptibility to antimicrobials in vitro. We then explored 
how GSH deficiency affects the fitness of P. aeruginosa in four mouse models of infection, 
including surgical wound, abscess, burn wound, and acute pneumonia models.    
1.9 P. aeruginosa requires GSH for normal growth in vitro 
In P. aeruginosa, GSH biosynthesis is catalyzed by a two-step reaction. In the rate-limiting 
first step, γ-glutamylcysteine synthetase, the product of the gshA gene, produces γ-
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glutamylcysteine. In the second step, GSH is produced from γ-glutamatecysteine by 
glutathione synthetase, the product of the gshB gene (206, 207). To study the importance 
of GSH biosynthesis in P. aeruginosa biology, we constructed a gshA deletion mutant 
(ΔgshA) in the P. aeruginosa strain PAO1 background. We chose to inactivate gshA and 
not gshB not only because it disrupts the first step in glutathione biosynthesis, but also 
because gshB mutants still produce γ-glutamylcysteine, which can partially compensate 
for GSH (220). This is likely the reason why P. aeruginosa gshA mutants generally have 
a more severe growth rate and antimicrobial tolerance defect than gshB mutants (71, 221). 
Previous studies have shown that P. aeruginosa ΔgshA has a growth defect in minimal 
media, but growth rates are restored to wild-type (WT) levels in LB broth (215). However, 
an explanation for the differences in growth rate for gshA mutants in the two media was 
unclear. To address this question, we measured the growth rates of P. aeruginosa WT 
and ΔgshA in several media. We tested MOPS (3-(N-morpholino)propanesulfonic acid) 
minimal medium supplemented with 20 mM glucose (MOPS-glucose), MOPS-glucose 
containing 1 mM GSH, MOPS-glucose containing yeast extract (5 g/L), MOPS-glucose 
containing tryptone (10 g/L), chemically defined media (CDM) (222), and LB broth. We 
selected 1 mM GSH because this concentration is within the range of typical intracellular 
GSH concentrations (215, 223-225). We chose 5 g/L yeast extract and 10 g/L of tryptone 
as these are the concentrations present in LB. Finally, CDM is a rich chemically defined 
media that contains all amino acids and nucleotides and many metabolites essential for 
growth, but it does not contain GSH (222). 
Consistent with previous studies (215), we observed a growth rate defect for P. aeruginosa 
ΔgshA compared to the WT in MOPS-glucose, but not in LB (Figure 1). While it was 
previously hypothesized that the reason for this difference in growth rate was stress 
caused by nutritional restriction in minimal media (215), we discovered that P. aeruginosa 
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ΔgshA also exhibited a growth rate defect in CDM, a rich defined medium, as well as 
MOPS-glucose + tryptone. These data indicate that nutritional stress is unlikely to be the 
cause of the growth rate defect for P. aeruginosa ΔgshA in MOPS-glucose. Importantly, 
the growth rate of the mutant was restored to WT levels with the addition of GSH or yeast 
extract. GSH is abundant in yeast cells (226), thus the growth rate of P. aeruginosa ΔgshA 
is likely restored to WT levels in LB due to the presence of GSH in yeast extract. 
These results underscore the importance of using a medium that does not contain GSH 
when studying GSH biosynthesis, since the presence of GSH in growth medium such as 
LB can confound interpretation of experimental results. For example, compared to WT, 
GSH-deficient P. aeruginosa mutants reportedly produce less biofilm when grown in M9 
minimal media (215) compared to LB (71), likely because of the high levels of GSH in the 
yeast extract component of LB (226). Furthermore, unbuffered GSH added to media at 
high concentrations, such as 10 mM, can significantly lower the pH of the media and 
induce an acid shock response in bacteria (209). Finally, even bacteria grown in the same 
media, but in different culture vessels or culture volumes, display greatly different oxidative 
stress responses (227). Taken together, the experimental growth environment should be 
carefully considered, and differences in growth conditions between laboratories likely 




Figure 1. Growth rates of P. aeruginosa WT and ΔgshA in different media. n = 3-5. P 
value ** < 0.01, **** < 0.0001 using two-way ANOVA followed by Bonferroni’s multiple 
comparisons test with 95% confidence interval. Error bars represent 1 standard error. 




1.10 P. aeruginosa requires GSH for protection against some disinfectants and 
antibiotics 
GSH has been implicated in tolerance to several antimicrobials. To kill bacteria during 
infection, neutrophils and macrophages produce ROS such as hydrogen peroxide (H2O2) 
and hypochlorous acid (HOCl) (228, 229). GSH is one of the cell’s primary mechanisms 
for protection against ROS (206, 207), and GSH-deficient P. aeruginosa mutants are 
sensitive to ROS-generating agents including methyl viologen and paraquat (71, 215). 
Several recent studies have also argued that different classes of bactericidal antibiotics, 
but not bacteriostatic antibiotics, can generate ROS and kill bacteria through secondary 
mechanisms (196, 230). In some Gram-negative bacteria, GSH also helps maintain 
cellular osmolality by regulating intracellular K+ (206, 213) and mutants that are deficient 
in either GSH biosynthesis or in K+ transport are hypersusceptible to antimicrobial 
peptides (AMPs) (231-234). 
To explore the role of GSH biosynthesis in protection from different antimicrobials in P. 
aeruginosa, we performed disc diffusion assays with a panel of disinfectants and 
antibiotics (Table 1). We grew P. aeruginosa WT and ΔgshA on MOPS-glucose + tryptone 
agar plates with or without 1 mM GSH, representing permissive and non-permissive 
conditions for the ∆gshA mutant, respectively. We tested two disinfectants: hydrogen 
peroxide and bleach (NaOCl), and six antibiotics: polymyxin B, colistin, ciprofloxacin, 
carbenicillin, tetracycline, and chloramphenicol. Polymyxin B and colistin are both 
bactericidal AMPs (64), ciprofloxacin and carbenicillin are both bactericidal antibiotics, and 
tetracycline and chloramphenicol are bacteriostatic antibiotics. 
As shown in Table 1, P. aeruginosa ΔgshA had a larger zone of inhibition (ZOI) compared 
to the WT when exposed to hydrogen peroxide or bleach, and the ZOI was restored to WT 
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levels with the addition of GSH. P. aeruginosa ΔgshA was also more susceptible to the 
bactericidal antibiotic ciprofloxacin; however, this enhanced susceptibility was not 
chemically complemented by addition of GSH. P. aeruginosa ΔgshA was also slightly 
more resistant to the bactericidal antibiotic carbenicillin (P = 0.079). Finally, we observed 
no difference in the ZOI for P. aeruginosa ΔgshA compared to WT when treated with the 
AMPs polymyxin B and colistin or the bacteriostatic antibiotics chloramphenicol and 
tetracycline. 
Taken together, these results show that P. aeruginosa GSH is critical for protection from 
ROS. In previous transposon sequencing (Tn-seq) experiments that assessed the fitness 
of thousands of P. aeruginosa mutants simultaneously upon exposure to antimicrobials, a 
similar fitness defect for P. aeruginosa gshA mutants was observed upon exposure to 
bleach, but not to H2O2 (221). This lack of a fitness defect upon exposure to H2O2 was 
likely due to rapid detoxification of H2O2 by P. aeruginosa catalases, which prevented 
identification of a number of functions important for P. aeruginosa H2O2 tolerance in that 
study (221). The importance of GSH for tolerance to ROS raises the possibility that GSH 
biosynthesis inhibitors may be a reasonable therapeutic strategy for enhancing bacterial 
clearance by host-generated ROS or certain antibiotics. However, this approach would 
likely require development of GSH biosynthesis inhibitors that are bacteria specific, as 
common non-specific GSH inhibitors, such as buthionine sulfoximine (BSO) (223) or 





Table 1. P. aeruginosa zones of inhibition following exposure to 8 antimicrobials. 
The average zone of inhibition (measured in millimeters ± standard error of the mean) 
for P. aeruginosa WT and ΔgshA with or without 1 mM glutathione (GSH) added to the 
media. n = 3-8 for each condition. P values < 0.05 by using two-way ANOVA followed by 
Bonferroni’s multiple comparisons test with 95% confidence interval are indicated in 
bold. 
  
Antimicrobial GSH WT ∆gshA P value 
Hydrogen peroxide - 38.0  ± 0.9 49.6 ± 1.9 <0.0001 
+ 38.3 ± 1.1 39.3 ± 1.2 >0.9999 
Bleach - 37.0 ± 2.1 47.4 ± 1.3 0.0002 
+ 21.3 ± 1.8 22.3 ± 2.2 >0.9999 
Polymyxin B - 13.8 ± 0.2 16.0 ± 0.4 >0.9999 
+ 13.8 ± 0.4 15.2 ± 0.6 >0.9999 
Colistin - 15.0 ± 0.3 18.1 ± 0.6 0.4750
 
+ 14.9 ± 0.3 16.0 ± 0.6 >0.9999 
Ciprofloxacin - 28.4 ± 0.9 35.8 ± 1.6 <0.0001 
+ 27.9 ± 0.8 36.6 ± 1.6 <0.0001 
Carbenicillin - 19.9 ± 1.5 14.3 ± 0.6 0.0789 
+ 17.6 ± 1.1 14.4 ± 1.3 >0.9999 
Tetracycline - 10.9 ± 0.8 8.8 ± 2.7 >0.9999 
+ 10.6 ± 0.7 12.3 ± 0.7 >0.9999 
Chloramphenicol - 14.3 ± 1.6 14.3 ± 1.2 >0.9999 
+ 13.3 ± 1.0 13.1 ± 0.8 >0.9999 
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The slight increase in tolerance to carbenicillin (Table 1) is likely due to the slower growth 
rate of P. aeruginosa ΔgshA in MOPS-glucose + tryptone (Figure 1), as it is known that 
slower growing cells are more resistant to the beta-lactam class of antibiotics (236, 237). 
This phenotype was mitigated by the addition of GSH, although this was due to an 
increase in tolerance of WT P. aeruginosa to carbenicillin in the presence of GSH. Thus, 
the mechanisms controlling carbenicillin tolerance and GSH is more complex than that 
observed for ROS. The mechanism of ciprofloxacin hypersusceptibility also appears 
complex, as tolerance of P. aeruginosa ΔgshA was not restored by addition of GSH. 
Finally, P. aeruginosa ΔgshA showed no change in tolerance to AMPs as has been 
observed in other bacteria (231), although this does agree with recent Tn-seq data 
showing that inactivation of gshA had no effect on P. aeruginosa fitness in the presence 
of polymyxin B (221). 
1.11 GSH biosynthesis provides a fitness benefit to P. aeruginosa in a mouse 
model of acute pneumonia, but is dispensable in surgical wound, abscess, 
and acute burn wound infections 
As discussed in Chapter 1, P. aeruginosa is a versatile pathogen that can infect multiple 
body sites, among the most common of which are soft tissues and lungs. P. aeruginosa 
is one of the most common organisms isolated from human chronic wound infections, burn 
wound infections, and hospital-associated acute pneumonia, and the presence of P. 
aeruginosa in these infections is also associated with increased infection severity and 
mortality (33, 41, 63, 64, 238). Previous studies (71, 155, 176, 214, 215), as well as our in 
vitro experiments, suggest an important role for GSH biosynthesis for P. aeruginosa during 
infection. Here, we comprehensively assessed the fitness of P. aeruginosa WT and ΔgshA 
in four mouse models of infection: the surgical wound, abscess, acute burn wound, and 
acute pneumonia models. 
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We first tested two non-lethal soft tissue infection models. The surgical wound mouse 
model involves surgically removing a full-thickness area of skin from the shaved backs of 
the mice, applying a semipermeable bandage over the wound, and administering the 
bacterial inoculum to the wound topically underneath the bandage (4, 29, 239, 240). The 
abscess model involves a subcutaneous injection of bacteria into the shaved inner thigh 
of the mice (241, 242). For both models, we infected mice with ~106 CFUs of P. aeruginosa 
WT or ΔgshA and enumerated bacterial loads after 4 and 3 days post-infection for the 
surgical wound and abscess models, respectively. Results from these experiments 
revealed no significant difference between bacterial loads for the ΔgshA mutant compared 
to the WT in the surgical wound model (Figure 2A) or in the abscess model (Figure 2B).  
We next tested two lethal mouse infection models, the acute burn wound and acute 
pneumonia models. The mouse burn wound model (4, 174) involves exposing the shaved 
backs of mice to  90°C water for 10 seconds, creating a uniform third-degree burn. The 
acute pneumonia model (175, 243) involves a non-invasive intratracheal administration of 
bacteria directly into the lung. We infected mice with ~103 CFU and 2.5x107 CFU P. 
aeruginosa WT and ΔgshA for the burn model and the pneumonia model, respectively. 
Survival was monitored over a period of seven days.
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Figure 2. Surgical wound and abscess mouse infection models. Mice were infected with 
approximately 1x106 CFUs of P. aeruginosa WT or ΔgshA in the (A) surgical wound and 
(B) abscess mouse models of infection. Mice were sacrificed at 4 and 3 days post-
infection, respectively. Mouse infections were performed with three mice in each group 






Figure 3. Burn wound and acute pneumonia infection models. (A) For the mouse burn 
wound infection model, mice were infected with approximately 1x103 CFUs of WT or 
ΔgshA P. aeruginosa. Experiments were performed with five mice in each group and 
repeated independently twice, n = 10.  (B) For the mouse acute pneumonia infection, 
mice were infected with approximately 2.5x107 CFUs (2X LD50) of P. aeruginosa.  Mouse 
infections were performed with five mice in each group and repeated independently 
three times, n = 15. All mice were monitored for 7 days or until moribund and humanely 
euthanized. Results are represented as Kaplan-Meier survival curves; differences in 








As shown in Figure 3A, there was no significant difference in survival between mice 
infected with P. aeruginosa WT or ΔgshA in the burn wound model. However, in the 
pneumonia model (Figure 3B) we observed a modest but statistically significant increase 
in survival for mice infected with P. aeruginosa ΔgshA compared to the WT. The 
pneumonia model data are consistent with a previous study showing decreased bacterial 
loads in the lung for P. aeruginosa ΔgshA in a mouse acute pneumonia model (176). The 
increased importance of GSH biosynthesis for P. aeruginosa in the lung and not soft tissue 
is likely explained by the fact that GSH-deficient P. aeruginosa mutants have reduced 
expression of T3SS (176) which is important for lung pathogenesis (64), as discussed in 
Chapter 1.5.  
1.12 Discussion 
While P. aeruginosa ΔgshA does show a statistically significant decrease in lethality in the 
pneumonia model, the effect is quite modest compared to other mutants that are 
considered attenuated in this model, such as rhlR (175) and aroA (244). These results, 
along with the lack of an infection phenotype for P. aeruginosa ΔgshA in the burn, surgical 
wound and abscess mouse models reveal that GSH biosynthesis plays little if any role in 
virulence in commonly used mouse models of P. aeruginosa infection. This result is 
somewhat surprising given the role of GSH in the pathogenesis of other bacteria, the high 
susceptibility of P. aeruginosa ΔgshA to ROS (Table 1), as well as the heightened 
inflammatory responses, oxidative stress and tissue GSH depletion that are characteristic 
of the mouse models that we used (18, 19, 34-36, 245).  
One simple explanation for our results is that P. aeruginosa can scavenge sufficient 
bioavailable glutathione from the host in these infection models, despite the lowered tissue 
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GSH levels associated with infection, thus mitigating the ΔgshA phenotype. This 
explanation is supported by previous Tn-seq studies showing that P. aeruginosa gshA 
mutants were more fit in the burn and surgical wound mouse models than in a minimal 
MOPS-succinate medium without added GSH (4). These studies also indicate that the 
gshA mutant is not trans-complemented by the other P. aeruginosa mutants in the 
infection, thus GSH does not appear to be a social good that is shared amongst community 
members (as discussed in Chapter 1.6)  (4). It should be noted that we followed commonly 
used methodology in our experiments including method of inoculation and inoculating 
dose. Thus, while we think it is unlikely based on the diversity of models and inoculating 
doses used, it is possible that altering these parameters could change the outcome of our 
experiments and reveal a role for GSH biosynthesis in P. aeruginosa pathogenesis. 
Due to its potent antioxidant properties, there is increasing interest in using GSH as a 
treatment strategy for a variety of human pathologies. Uncontrolled oxidative stress is a 
key pathophysiological feature of chronic wounds (246), burn wounds (34), and 
pneumonia (245, 247). Experimental rodent and human clinical studies have shown that 
administration of GSH can result in significantly improved healing, reduced tissue damage, 
and lower mortality in chronic wounds (248, 249), burn wounds (35, 250, 251), and 
pneumonia (252-254). However, it is unclear how administration of GSH in human 
subjects will affect the physiology of P. aeruginosa during infection. While our in vitro data 
suggest that inhibiting GSH biosynthesis may render P. aeruginosa more susceptible to 
ROS, addition of GSH can restore tolerance to the gshA mutant and in some cases alter 
the tolerance of WT P. aeruginosa (Table 1). Thus, GSH administration may in fact 
promote unwanted P. aeruginosa-mediated infection phenotypes. Further studies are 
necessary to elucidate the safety and efficacy of GSH administration during P. aeruginosa 
 38 
infection. In conclusion, our results provide new and complementary data regarding the 
role of GSH in P. aeruginosa virulence.    
1.13   Materials and methods 
Bacterial strains and growth media.  
P. aeruginosa strain PAO1 was obtained from Colin Manoil (University of Washington). 
The PAO1 ∆gshA deletion mutant was constructed as previously described (5). Briefly, 
~700-bp fragments flanking the gshA gene were amplified by PCR with Phusion hot start 
II DNA polymerase (Thermo Scientific, Waltham, MA) to replace the coding sequence with 
the sequence 5′-GCGGCCGCC-3′ flanked by the native start codon. The PCR primers 
were 5’-TTCTGCAGGTCGACTCTAGACGAGAAGGTCGAAGGCCAGC-3’ and 5’-
CCGGCTTGGCTCGGGATTCCTTGTGATCGCGT-3’ for the upstream region and 5’-
GAATCCCGAGCCAAGCCGGCGCGCC-3’ and 5’-
GAATTCGAGCTCGAGCCCGGGCTTGCTGGACGCATCCGGC-3’ for the downstream 
region. These two amplicons and the suicide vector pEXG2 (255) were assembled using 
Gibson assembly as described previously (256), transformed initially into Escherichia coli 
DH5α λpir, and then transformed into E. coli SM10 λpir for conjugation into P. aeruginosa 
strain PAO1. Successful transconjugates were selected for with gentamicin followed by 
selection on sucrose to obtain the chromosomal deletion. This mutation was then verified 
by PCR. For routine growth, P. aeruginosa strains were grown on LB agar plates 
overnight. Unless otherwise stated, overnight P. aeruginosa cultures from single colonies 
on the LB agar plates were grown in 3-(N-morpholino)propanesulfonic acid acid (MOPS)-




 P. aeruginosa WT PAO1 or ΔgshA were grown overnight in either MOPS-glucose, 
MOPS-glucose + 1mM GSH (L-Glutathione reduced, Sigma), MOPS-glucose + 5g/L yeast 
extract (Sigma), MOPS-glucose + 10g/L Bacto tryptone (Fisher), LB broth (Fisher), or a 
rich, chemically defined medium (CDM) (222). Subcultures were diluted in the same 
medium to an OD600 of 0.05 and grown in culture tubes at 37°C shaking. OD600 
measurements were recorded by diluting subculture samples to between 0.09 and 0.5. 
The generation times were calculated using OD600 measurements taken during 
exponential growth.  
Disc diffusion assays  
Overnight P. aeruginosa cultures were grown in MOPS-glucose, adjusted to an OD of 0.4, 
and swabbed onto MOPS-glucose + tryptone agar plates (MOPS-glucose supplemented 
with 10g/L Bacto tryptone, Fisher) with or without added 1mM GSH. Sterile quarter-inch 
filter discs were placed on the center of each plate, and 20 µL of each compound tested 
was pipetted onto the disc. Stock concentrations of each antibiotic (Polymyxin B, Sigma; 
Colistin, Sigma; Ciprofloxacin, Sigma; Carbenicillin, Alfa Aesar; Tetracycline, Sigma; 
Chloramphenicol, IBI Scientific) were dissolved at concentrations of 1 mg/ml. For the 
disinfectants, 3% hydrogen peroxide or 0.85% sodium hypochlorite was used. An 
additional 20 µL of hydrogen peroxide was added onto the hydrogen peroxide plates after 
7 hr of growth. Plates were incubated at 37°C overnight. Two measurements of the 
diameter of the zone of inhibition were recorded for each plate and averaged.  
Mouse infections 
All mouse procedures were carried out in strict accordance with established guidelines at 
each respective university following recommendations in the Guide for the Care and Use 
of Laboratory Animals (257) of the National Institute of Health as well as local, state, and 
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federal laws. For all mouse experiments, P. aeruginosa strains were struck on LB agar 
plates, grown overnight in LB broth, then subcultured in LB broth to logarithmic phase 
growth. Bacterial inoculums were diluted to the appropriate OD600 in PBS. 
For the mouse acute thermal injury infection model (also referred to as the “mouse burn 
wound model’) (4, 174), all animals were treated humanely and in accordance with 
protocol number 96020 approved by the Institutional Animal Care and Use Committee 
(IACUC) at Texas Tech University Health Sciences Center in Lubbock, TX. Adult 6-8 
week-old female Swiss Webster mice (Charles River Laboratories, Inc.) weighing between 
20 and 25 grams, were anesthetized by intraperitoneal injection of 100 mg/kg sodium 
pentobarbital (Nembutal; Diamondback Drugs). Their backs were then shaved and the 
remaining hair was removed with a depilatory agent (Nair). Prior to injury, 0.5 mg/kg 
buprenorphine (ZooPharm) was administered subcutaneously for pain management. A 
15% total body surface area, third-degree, full-thickness thermal injury was induced by 
submerging an exposed area of the dorsal surface in a 90°C water bath for 10 seconds. 
Mice were then given a subcutaneous injection of 500 µl physiological saline for fluid 
support. 100 μl of approximately 103 CFU of either P. aeruginosa PAO1 WT or ΔgshA 
were injected subcutaneously directly underneath the freshly injured tissue. The animals 
were then monitored for 7 days post-injury and infection for signs of sepsis (lethargy, 
weight-loss, tremors, etc.). In the event that mice became moribund, they were euthanized 
by intraperitoneal injection of 200 μl (390 mg/ml) Fatal-Plus (Vortech Pharmaceuticals, 
Ltd.) and included in the experimental results. Surviving mice were similarly euthanized 
after the 7-day experimental end-point.  
For the mouse surgical incision infection model (also referred to as the “mouse chronic 
wound model”) (4, 29), Female 6-8 week-old adult Swiss Webster mice weighing between 
20 and 25 grams were anesthetized by intraperitoneal injection of 100 mg/kg sodium 
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pentobarbital. Their backs were then shaved and the remaining hair was removed with a 
depilatory agent. Prior to injury, animals were given 0.5 mg/kg buprenorphine 
subcutaneously for pain management. A dorsal, 1.5 x 1.5 cm excisional skin wound to the 
level of the panniculus muscle was administered. Wounds were then covered with a 
transparent, semipermeable polyurethane dressings (OPSITE dressings). 100 μl of 
~1x106 CFU of bacterial cells were injected under the dressing on top of the wound to 
establish the infection. The adhesive dressing prevents contractile healing and ensures 
that these wounds heal by deposition of granulation tissue, much like human wounds. 
After four days post-infection the animals were sacrificed by intraperitoneal injection of 
200 μl (390 mg/ml) Fatal-Plus and wounds were harvested. Wounds were homogenized 
in PBS for 30 seconds in BeadBug tubes with 2.8-mm steel beads (Sigma-Aldrich) using 
a Mini-Beadbeater-16 (BioSpec Products). Bacterial loads in the wounds were 
enumerated by serial dilution and plating on Pseudomonas Isolation Agar (Sigma).  
For the mouse acute pneumonia model (175, 243), all animals were treated humanely and 
in accordance with protocol number DAR-201700441 approved by the IACUC at Emory 
University in Atlanta, GA. Adult 6-8 week-old female BALB/c mice (Jackson Laboratories, 
Bar Harbor, ME) were anesthetized by an intraperitoneal injection of 200 μl of a mixture 
of (80 mg/kg) ketamine and (10mg/kg) xylaxine  (Med-Vet International). Mice were 
infected by non-invasive intratracheal instillation of 50 μl of ~2.5x107 CFU (2xLD50) of P. 
aeruginosa PAO1 WT or ΔgshA. The animals were then monitored for 7 days post-
infection for survival. In the event that mice became moribund, they were humanely 
euthanized by CO2 asphyxiation and included in the experimental results. Surviving mice 
were similarly euthanized after the 7-day experimental end-point.  
For the mouse abscess model (241, 242), all animals were treated humanely and in 
accordance with protocol number 00136 approved by the IACUC of The University of 
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Texas at Austin (Austin, TX) and protocol number A17086 approved by the IACUC of 
Georgia Institute of Technology (Atlanta, GA). Adult 6-8 week-old female Swiss Webster 
mice (Charles River Laboratories, Inc.) were anesthetized with inhaled isoflurane (1-3% 
for maintenance; up to 5% for induction) in oxygen from a precision vaporizer. While 
anesthetized, their inner thigh was shaved and any remaining hair removed with a 
depilatory agent (Nair). A 75% ethanol solution was used to clean the area prior to 
infection. Abscesses were initiated by injecting 100 µL of approximately 1x106 CFU of P. 
aeruginosa PAO1 WT or ΔgshA subcutaneously into the inner thigh. Mice were monitored 
for signs of sepsis, and in the event that mice became moribund, they were humanely 
euthanized by CO2 asphyxiation. Three days post-infection, mice were euthanized by CO2 
asphyxiation and abscesses were harvested. Abscesses were homogenized in PBS for 
30 seconds in BeadBug tubes with 2.8-mm steel beads (Sigma-Aldrich) using a Mini-
Beadbeater-16 (BioSpec Products). Bacterial loads were enumerated by serial dilution 
and plating on Pseudomonas Isolation Agar (Sigma).  
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TRANSCRIPTOMIC AND PROTEOMIC SIGNATURES OF 
GROWTH RATE IN PSEUDOMONAS AERUGINOSA GROWN 
IN CHEMOSTATS 
 
1.14 Background and significance 
Bacteria live in diverse, continuously fluctuating environments. To survive, they must be 
able to adapt to rapid changes in environmental conditions such as temperature, pH, 
osmolarity, oxygen level, nutrient availability, and the presence of stressors like toxins and 
antibiotics. Accordingly, bacteria have evolved sophisticated systems for sensing their 
environment and adjusting their cellular growth rate to suit their current environmental 
conditions (258-260). Many important aspects of cellular physiology change with respect 
to growth rate (also known as generation time). For example, cellular morphology and 
macromolecular composition vary greatly with growth rate; compared to slow-growing 
cells, fast-growing cells are larger and contain more DNA, RNA, protein, lipids, 
carbohydrates, and ribosomes (258, 261, 262). Importantly, clinically-relevant cellular 
behaviors are also dependent on generation time, such as production of virulence factors 
(263, 264), stress resistance (265-267) and antibiotic susceptibility (268-270). However, 
despite the importance of the relationship between growth rate and cellular physiology, 
most laboratory experiments are performed during only the rapid logarithmic phase of 
growth, leaving cellular physiology at slower growth rates is less well understood.  
During infection, bacteria are thought to grow at a wide range of doubling times depending 
on the stage of infection, activity of the immune system, and nutrient availability. These 
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growth rates are likely slower than the rapid, maximal growth rates achieved in standard 
laboratory cultures. Determining the rate of bacterial growth during infection is not trivial, 
but several approaches have been used, including use of superinfecting phage (271), 
radio isotope labeling (262), and quantitative fluorescence in situ hybridization (FISH) 
(272-274). Depending on the infecting organism, culturing conditions, type of infection and 
measurement technique, recorded bacterial generation times during infection range from 
1 to 10 hours, or they are found to be non-growing (262, 271-273). This is in contrast to 
the in vitro maximal generation times for the same organisms ranging between about 0.5 
and 1 hr (262, 271-273). This information emphasizes the importance of better 
understanding both how quickly bacteria grow in the host during infection and also how 
bacterial physiology changes with growth rate.  
Knowing, and controlling for, the impact of growth rate on cellular physiology is also 
critically important for more accurately interpreting experimental results. Experimental 
conditions of interest often inadvertently affect cellular growth rate; for example, 
experiments involving changes in media composition, oxygen availability, and exposure 
to stressors will also cause a change in growth rate. However, without a growth-rate 
control, it is often difficult if not impossible to distinguish between the physiological effects 
caused by the experimental condition of interest and those caused by changes in growth 
rate. This problem is particularly pronounced in high-throughput –omics experiments, such 
as differential transcriptome or proteome profiling. For example, in an RNA-seq 
experiment comparing yeast subjected to a variety of stressful conditions, many genes 
were initially identified as part of a general stress tolerance response (275). However, 
when compared to yeast grown in the same media but at different growth rates, most of 
these “stress tolerance genes” were actually strongly correlated with slow growth (276). 
Furthermore, in many published datasets, the cellular growth rate is often unmeasured 
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and left undefined as simply “logarithmic phase growth”, making it difficult to compare data 
across experiments. For these reasons, it is important to carefully consider the effect of 
growth rate when interpreting experimental results.  
Precisely controlling growth rate in the laboratory can be challenging. Common methods 
of altering bacterial growth rate include varying media composition (258, 277), 
temperature (278, 279), or adding stressors (280, 281). However, changing each of these 
conditions will also cause alterations in cellular physiology that are independent of growth 
rate. Furthermore, use of traditional closed culture systems, such as culture tubes or 
flasks, results in measurements that are imprecise and variable. This is because the 
environment in a closed-culture system is constantly in flux. Following initial inoculation, 
bacteria grow at a maximal rate, but as nutrients are depleted, the pH changes and toxic 
metabolic byproducts accumulate, causing growth to slow and cells transition to stationary 
phase. A more precise method to control cellular growth is the use of a continuous culture 
system called a chemostat (282-285). In a chemostat, bacteria grow at a near steady-
state equilibrium where both the cellular density and growth rate is kept constant over an 
indefinite period of time. The media contains a growth-limiting concentration of an 
essential nutrient, which allows the bacterial density to be kept near-constant. The 
bacterial growth rate is thus proportional to the media flow rate. Previous studies have 
demonstrated that cellular physiological responses during growth in a chemostat are more 
consistent and reproducible than growth in culture tubes or flasks (282).  
As discussed in section 1.7, there are many laboratory models of bacterial infection, 
including in vitro, invertebrate and vertebrate models. However, every model has its own 
limitations in how accurately it replicates human infections. One powerful advantage of 
RNA-seq is that it can be used on bacteria sampled directly from human infections. RNA-
seq works by capturing a gene expression “snapshot” from bacterial populations. RNA-
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seq data from human infection samples performed in this lab (286, 287) and in others 
(288-290) have been used to infer attributes of the human infection environment (such as 
oxygen or iron availability) and to identify functions that may be important for bacterial 
fitness during infection. However, one issue when interpreting RNA-seq data is that there 
is a general assumption that mRNA expression is proportional to protein expression. For 
example, if we observe increased mRNA expression for a gene in a human infection 
sample, we assume that the corresponding protein expression will also be higher. 
However, due to disparate rates of mRNA and protein degradation, as well as 
mechanisms of post-transcriptional, translational, and post-translational regulation, for a 
given gene the corresponding mRNA and protein levels may be weakly correlated (291-
294). Importantly, these correlations are not static, and can vary by strain (292) or growth 
phase (291).  
For this study, we sought to characterize global patterns of gene and protein expression 
over a broad range of growth rates in P. aeruginosa. We generated a carefully controlled 
benchmark dataset by culturing P. aeruginosa in MOPS-succinate minimal medium at 
several defined growth rates using a chemostat. Bacteria were sampled 3.3-, 6.0-, 13.8-, 
and 25.3-hr doubling times, and mRNA and protein abundances were quantified using 
RNA-seq and proteomics mass spectrometry, respectively. From our analysis we observe 
only modest correlations between mRNA and protein expression, and these correlations 
differ by growth rate. Both mRNA and protein expression are impacted by growth rate, but 
there are distinct effects on each. There tends to be more variation in the mRNA data 
compared to the protein data. Globally, for a given individual gene, the mRNA has a 
greater range and variation in expression across growth rates than the protein. At the 
same time, differences in the protein-to-mRNA ratio for a given gene are driven largely by 
protein expression rather than mRNA expression.  
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These results demonstrate that the assumption of a 1:1 protein to mRNA ratio doesn’t 
hold. Rather, the relationship between mRNA and protein expression, and how they are 
affected by changes in cellular growth rate, are complex.  
1.15 mRNA and protein expression levels cluster by growth rate  
Commercially available chemostats are typically very expensive. For this study, we 
modified a previous design (282) for a simple assembly built from common laboratory 
glassware and equipment that should be affordable for most laboratories. Using this 
chemostat, we grew P. aeruginosa strain PA14, a clinical human chronic wound isolate, 
in MOPS minimal medium containing 10mM succinate as the sole carbon and energy 
source (MOPS-succinate). We started with MOPS-succinate minimal media because P. 
aeruginosa succinate metabolism is relatively simple, well characterized, and reproducible 
(4, 221, 286).  We sampled bacteria maintained at 3.3-, 6.0-, 13.8-, and 25.3-hr doubling 
times. This range spans the doubling times that P. aeruginosa is likely to grow at during 
human infection (262, 271-273). We collected 16 samples for RNA-seq analysis (4 from 
each growth rate) and 10 samples for proteomics mass spectrometry analysis (3 samples 
from the two extremes and 2 for the middle growth rates). Mass spectrometry was 
performed on cell pellets, so secreted proteins were not included in our analysis. All 
bacterial cultures were allowed to acclimate to the chemostat conditions for two days 
(confirmed by steady OD600) before collection. All samples were collected at least one day 
apart. To minimize batch effects, mRNA and protein samples were collected from separate 
chemostat batches, and samples from the same growth rate were collected from at least 
two different chemostat batches (except protein samples from the middle two growth 
rates).    
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First, to explore global relationships between growth rate and mRNA or protein 
expression, we performed a principal component analysis (PCA). To normalize by 
sampling depth, raw mRNA and protein sample counts were scaled to 1,000,000, then 
log2 transformed. As demonstrated in Figure 4, for both the mRNA and protein data, 
samples tend to cluster by growth rate. The proportion of variance across the dataset that 
is explained by PC1 and PC2 was also very high: 44.1% and 23.5%, respectively for the 
mRNA data, and 30.6% and 13.1%, respectively for the protein data. For the mRNA data, 
samples of bacteria grown at the extreme growth rates (3.3- or 25.3-hr doubling times) 
clustered the most tightly together, while the middle growth rates (6.0- and 13.8-hr 
doubling times) had greater variability. The cumulative value for PC1 and PC2 is also 
higher for the mRNA samples (67.6%) compared to protein (43.7%). Taken together, 
these results suggest that for P. aeruginosa, alterations in growth rate alone, while keeping 
other environmental conditions constant, results in significant changes in global mRNA 
and protein expression. Furthermore, in general there is more variability in mRNA 
expression compared to protein expression in relationship to changing growth rate.  
1.16 mRNA and protein are only modestly correlated, and vary with growth rate 
As mentioned previously, the general assumption when interpreting RNA-seq data is that 
the relationship between mRNA and protein expression is 1:1. To explore how well this 
assumption holds, we next sought to compare and contrast patterns of mRNA and protein 
expression across growth rates. For this analysis, and all subsequent analyses, we used 
depth-normalized, log2 transformed counts for mRNA and protein, and included only 
genes with non-zero counts for both mRNA and protein samples (3903 genes). First, we 
examined the distribution of the protein (Figure 5A) and mRNA (Figure 5B) expression 
level for each gene averaged across all 4 growth rates. The median expression value for 
protein is 4.3, while the median expression value for mRNA is 6.4. We can see that even 
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after normalization, the protein samples tended to have lower counts compared to the 
mRNA. However, the range of protein expression across all genes appears more uniform 
or stable, while the peak for the mRNA is much more pronounced, and the overall 
distribution appears more variable. Specifically, for protein, the 1st and 3rd quarter 
expression values for protein are 2.27 and 6.44, respectively, while for mRNA they are 
5.24 and 6.51. Put another way, the sample quantile 5% and 95% probabilities for protein 
are 0.52 and 9.84, respectively; for mRNA they are 3.39 and 9.74, respectively. Next, we 
calculated the Spearman's rank correlation coefficient (SpR) between mRNA and protein 
expression levels for P. aeruginosa averaged across all growth rates (Figure 6). We 
observe only a modest correlation (SpR = 0.59) between protein and mRNA. This means 
that generally for a given gene as mRNA expression increases, the corresponding protein 
also increases. However, there is considerable noise and outliers. To examine how these 
correlations may be affected by growth rate, we calculated the SpR for mRNA and protein 
samples separated by growth rate (Figure 7). While overall the SpR were similar across 
growth rates, the fastest growth rate (3.3-hr doubling) had the highest correlation (SpR = 
0.63), while one of the middle growth rates, 6.0-hr doubling, had the lowest correlation 
(SpR = 0.54). These results suggest that for a given gene, mRNA and protein levels are 
often not 1:1, and these correlations can be affected by the rate at which a cell is dividing.  
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Figure 4. PCA of mRNA and protein chemostat samples. PCA was performed on (A) 





Figure 5. Distribution of mean expression levels. For each gene, protein and mRNA 
expression counts were normalized by depth, log2 transformed, and averaged across all 




Figure 6. Correlation between average mRNA and protein expression. Each point 
represents a gene. For each gene, protein and mRNA expression counts were 
normalized by depth, log2 transformed, and averaged across all 4 growth rates. The 
Spearman's rank correlation coefficient (SpR) between mRNA and protein is indicated in 
the graph’s tittle. 
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Figure 7. mRNA and protein expression are only modestly correlated, and vary with growth 
rate. Each point represents a gene. mRNA and protein counts were normalized by depth 
and log2 transformed. Graphs are ordered from fastest to slowest growth rates (A-D). The 
Spearman's rank correlation coefficient (SpR) between mRNA and protein levels for each 
growth rate are indicated in each graph’s tittle.  
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1.17 Variables affecting mRNA-to-protein ratios  
We next attempted to identify variables that may explain the discrepancy between mRNA 
and protein correlations. In theory, for each gene we could apply a conversion factor to 
the mRNA in order to predict the corresponding protein level. A simple conversion factor 
could be the ratio of protein expression to mRNA expression. To calculate this ratio, we 
subtracted the log2 mRNA expression level from the log2 protein expression level, and 
averaged this value across the 4 growth rates. A distribution of these protein-to-mRNA 
ratios is shown in Figure 8.  2917 genes, or 74%, had the absolute value of the log2 fold-
change (|L2FC|) > 1, indicating that for most genes, there is at least a two-fold difference 
in expression between the corresponding mRNA and protein. The median protein-to-
mRNA ratio is -1.9, meaning that for over half of genes, the mean RNA expression level 
was higher than the mean protein expression level. This is consistent with results from 
Figure 5, which showed generally higher RNA expression than protein expression. There 
is also a considerable range of protein-to-mRNA ratios, from 2-10.0 to 28.7, or between a -







Figure 8. Ratio between protein and mRNA expression levels. For each gene, the log2 
transformed mRNA expression values were subtracted from the log2 transformed 
protein values, then averaged across all 4 growth rates.  
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 To explore this relationship further, we plotted mean protein (Figure 9A) or mRNA 
(Figure 9B) expression against the ratio of protein-and-mRNA expression, or the 
“conversion factor”.  Strikingly, there is a strong SpR between the protein/mRNA ratio and 
mean protein expression (SpR = 0.76), but not for mRNA expression (SpR = -0.02). These 
results indicate that for a given gene, as protein expression increases, so too does the 
ratio between protein and mRNA levels. This relationship is not a mathematical artefact 
due to protein expression being present on both axes, because the mRNA expression is 
not always proportional to the protein expression. In other words, if the difference between 
protein and mRNA was constant, then even if the mean protein expression was higher, 
then the slope between mean protein expression and protein/mRNA would be zero.  
To investigate what variables may be driving this relationship, we next examined the range 
of protein or mRNA expression levels across growth rates. The range represents the 
degree to which mRNA or protein expression varies between growth rates for a given 
gene. To calculate the range for each gene, we subtracted the minimum expression value 
from the maximum expression value across the 4 growth rates for either mRNA or protein. 
As shown in Figure 10, the dynamic range for mRNA is much greater than that for protein. 
2206 (57%) genes have an mRNA range <1, or less than a 2-fold change across all growth 
rates. In contrast, 3443 genes (88%) have a protein range <1. The largest single mRNA 
range is 26.4 (84-fold) while the largest protein range is 24.8 (28-fold). This means that 











Figure 9. Mean protein or mRNA expression levels vs. the ratio of protein-to-mRNA. 
Each point represents a gene. For each gene, protein and mRNA expression counts 
were normalized by depth, log2 transformed, and averaged across all 4 growth rates. 
The ratio of protein-to-mRNA was calculated by subtracting the log2 transformed mRNA 





Figure 10. The range of protein and mRNA expression within a gene across growth 
rates. Protein and mRNA expression values were normalized by depth, log2 
transformed, and averaged across all 4 growth rates. The range was calculated for each 
gene by subtracting the minimum expression value was from the maximum expression 









Knowing that changes in growth rate cause a greater variation in mRNA expression than 
protein expression, we next wanted to assess the effect that growth rate has on the 
protein-to-mRNA ratio. We calculated a new variable that represents the change in the 
protein-to-mRNA ratio with respect to growth rate, or the proportional variation in the 
conversion factor. As in Figure 8, for each gene we subtracted the log2 mRNA expression 
level from the log2 protein expression level to get the protein-to-mRNA ratio. We then 
subtracted the maximum protein-to-mRNA ratio from the minimal protein-to-mRNA ratio 
between the 4 growth rates for each gene. A distribution of the proportional variation in 
the correlation factor values is shown in Figure 11. 1647 genes (42%) had a value > 1, 
meaning that the difference in mRNA-to-protein ratios across the 4 growth rates is greater 
than 2-fold. In other words, for a given gene, a cell’s generation time can often impact the 
correlation between protein and mRNA. 
To explore this relationship further, we then plotted the interaction between the 
proportional variation in the correlation factor and the protein range (Figure 12A) or mRNA 
range (Figure 12B). Interestingly, there is a strong correlation with the mRNA range (SpR 
= 0.78), but not with the protein range (SpR = -0.17). This indicates that it is mainly the 
variation in mRNA expression across growth rates, rather than protein expression, that is 
driving the variation in protein-to-mRNA ratios.  
Finally, a correlation matrix, summarizing the interactions between all of the variables 
discussed thus far (mean protein and mRNA expression, protein and mRNA range, 
protein-to-mRNA ratio, and proportional variation in protein-to-mRNA ratio), is presented 





Figure 11. Variation in protein-to-mRNA ratios across growth rates. For each gene, the 
protein-to-mRNA ratio was calculated by subtracting the log2 mRNA expression level 
from the log2 protein expression level. The maximum protein-to-mRNA ratio was then 
subtracted from the minimal protein-to-mRNA ratio across the 4 growth rates to 
determine the final proportional variation in protein-to-mRNA ratio for each gene.  
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Figure 12. The relationship between range and variation in protein-to-mRNA ratio. The 
protein or mRNA ranges were calculated for each gene by subtracting the minimum 
expression value was from the maximum expression value between the 4 growth rates. 
Protein and mRNA expression values were normalized by depth, log2 transformed, and 
averaged across all 4 growth rates. The protein-to-mRNA ratios were calculated by 
subtracting the log2 mRNA expression level from the log2 protein expression level. The 
variation in protein-to-mRNA ratios was determined by subtracting the maximum protein-
to-mRNA ratio from the minimal protein-to-mRNA ratio between the 4 growth rates for 












RNA-seq is a powerful tool for profiling gene expression, and it can even be used on 
bacteria sampled directly from human infections (286, 287). However, it has limitations. 
When interpreting RNA-seq data, changes in mRNA expression are assumed to result in 
proportional changes in protein expression. As our results have shown, mRNA and protein 
levels are only somewhat correlated, and these correlations can change with growth rate. 
As shown in Figure 7 and 8, when averaging across all of the growth rates, the SpR was 
0.59. When the data is separated by growth rate, we observed a maximum SpR of 0.63 
(3.3-hr doubling) and a minimum SpR of 0.54 (6.0-hr doubling). The correlations that we 
calculated are consistent with those reported in other studies (291, 292).  
We then explored how variables, such as the mean protein and mRNA expression, the 
range of protein and mRNA expression, protein-to-mRNA ratio, and proportional variation 
in protein-to-mRNA ratio, may explain the incongruity between mRNA and protein 
correlations. As shown in Figure 5, when averaged across all growth rates, there is more 
variation in mRNA expression than protein expression, with the mRNA having a higher 
median and sharper peak than the protein. However, the range of expression across the 
genome and averaged across growth rates is higher for protein than mRNA. Likewise, as 
shown in Figure 10, there is a stark contrast in the mRNA range, or the difference in 
mRNA expression within a gene across growth rates, compared to the protein range. This 
variation in mRNA expression across growth rates appears to be driving the variance in 
protein-to-mRNA ratios across growth rates (Figure 12). In contrast, it is the mean protein 
expression, rather than the mean mRNA expression, that is strongly correlated with the 
protein-to-mRNA ratio (Figure 9).  
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We calculated protein-to-mRNA ratios, or conversion factors, for roughly 3900 P. 
aeruginosa genes. These conversion factors could potentially be used to more 
accurately predict protein abundance from RNA-seq data, especially if the growth rate is 
known. However, caution should be used, as over 40% of these conversion factors vary 
by more than two-fold across our growth rates (Figure 11). One limitation of our dataset 
is that we performed mass spectrometry on cell pellets, so secreted proteins weren’t 
included. Future studies could involve collecting filtered chemostat media in order to 
include secreted proteins. Another limitation of our dataset is that we only used one 
strain and one media condition. We know from previous experiments in our laboratory 
that the mRNA-to-protein ratios between P. aeruginosa strain PA14 and the laboratory 
strain PAO1 are generally highly conserved (292). However, nutrient availability has a 
major impact on gene expression (276, 295, 296). These conversion factors could be 
further refined by expanding our dataset to include chemostat conditions with different 
media and P. aeruginosa strains. With this approach we could identify genes with 
conversion factors that are conserved across strain, media condition, and growth rate.  
1.19 Materials and methods 
Chemostat assembly 
Our chemostat design is based on a previously described system (282) with minor 
modifications. The fresh media was contained in a 4 L glass Erlenmeyer flask (Pyrex). A 
rubber stopper (No. 10, Fisher) was fitted to the mouth of the flask. Three holes, 
approximately 5.9 mm in diameter, were drilled into the stopper. Two holes were fitted with 
short 12 cm glass tubes topped with air venting filter sterilizers (0.2 µm pore size, 50 mm 
diameter, VWR) to allow gas exchange and prevent vacuuming. The third hole was fitted 
with a long 40 cm glass tube from which to draw the media. Polytetrafluoroethylene 
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capillary tubing (Millipore) connected the media reservoir flask to the chemostat growth 
chamber. The tubing was hooked up to a 4 channel peristaltic pump (Watson Marlow), 
allowing precise control over the media flow rate.  
A 300 ml Berzelius beaker without a spout (Kimble) was used as the chemostat growth 
chamber. A rubber stopper (No. 13-1/2, Fisher) was fitted to the mouth of the beaker. Four 
holes were drilled into this stopper. The first hole, 6.0 mm in diameter, was fitted with a 1 
ml syringe (BD) with the plunger removed. Capillary tubing was inserted into the syringe 
and sealed in place with silicone aquarium sealant (VWR). The second hole, 16.5 mm, 
was fitted with a 15 ml polypropylene conical (Corning). The lower half of the conical was 
cut off, allowing bacterial culture samples to be obtained by unscrewing the conical lid and 
inserting a serological pipette into the growth chamber. The third hole, 6.7 mm, was fitted 
with a glass tube blown into a “J” shape to serve as the waste outflow tube. The surface 
of the waste tube was level with the 100 ml mark of the growth chamber. Capillary tubing 
was connected from the waste tube to a separate 4 L Erlenmeyer flask for waste collection. 
The fourth hole, 8.41 mm, was fitted with a 12 mm O.D. x 20 mm fritted gas dispersion 
tube (Chemglass). The gas dispersion tube was connected by capillary tubing to an air 
venting filter sterilizer, which in turn was connected to an aquarium air pump (Fusion Air 
Pump 200). This system pumps fresh, sterilized air to the growth chamber and creates a 
positive pressure in the chamber, which is necessary for expelling waste from the waste 
tube. The end of the fritted tube was lowered into the media in the growth chamber, 
constantly bubbling the media and allowing for continuous aeration and mixing.  
Bacterial strains and growth media  
Pseudomonas aeruginosa strain UCBPP-PA14 (PA14) was obtained from the MGH-
ParaBioSys:NHLBI Program for Genomic Applications, Massachusetts General Hospital 
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and Harvard Medical School, Boston, MA (http://pga.mgh.harvard.edu).  For each 
individual chemostat batch, bacteria were cultured from frozen glycerol stocks by streaking 
for isolation on LB agar plates and incubated at 37ºC overnight. For chemostat growth, 
bacteria were cultured in morpholinepropanesulfonic acid (MOPS) buffered minimal 
medium with 10 mM succinic acid as the sole carbon and energy source (MOPS-
succinate). All chemostat components including the MOPS buffed base were autoclaved 
for sterilization. After autoclaving, filter-sterilized FeSO4, MgsO4, and succinic acid were 
added aseptically to the MOPS buffed base. Media was pumped through the chemostat 
and left at room temperature overnight to confirm system sterility. A single P. aeruginosa 
colony was then picked and aseptically inoculated into the media in the chemostat growth 
chamber. Bacteria were then allowed to grow overnight at room temperature in order to 
reach a sufficient density. The chemostat was then transferred and maintained in a 37ºC 
warm room. The peristaltic pump was turned on and set to the appropriate flow rate. The 
bacteria were allowed to acclimate in the chemostat for 48 hrs before sampling. One 
sample was collected per day. The culture densities were determined by measuring the 
OD600 with a spectrophotometer. To mitigate batch effects, RNA-seq and mass spec 
samples were collected from separate chemostat batches. Bacterial generation times 
were calculated by dividing chemostat growth chamber volume (100ml) by the media flow 
rate. 
RNA-seq sample collection and library preparation  
To mitigate batch effects, for each growth rate samples were collected from at least two 
separate chemostat batches. For each individual RNA-seq sample, 5 ml of chemostat 
culture was collected and mixed well with 20 ml of the RNA preservative RNAlater (Sigma). 
Samples were stored at 4ºC for 24hrs to allow the solution to fully permeate the cells, and 
then stored at -80 ºC. RNA-seq libraries were prepared as previously described (221) with 
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minor modifications. Briefly, to extract RNA, samples were pelleted at 4°C, supernatant 
removed, and resuspended in 300 μl RNase-free TE buffer and 12 μl lysozyme (50 mg/ml, 
Thermo). To enzymatically lyse cells, samples were incubated at 37°C for 30 minutes. 1ml 
of RNA-Bee (Fisher) was added to each sample followed by transfer to 2 ml Bead Bug 
tubes containing 0.1-mm beads (Sigma). To homogenize the cells, tubes were bead 
beaten 3x for 30 seconds and chilled on ice for 1 minute in-between bead beatings. Cells 
were then transferred to 1.5 ml tubes with 0.2 ml chloroform (Fisher) added. Samples were 
vortexed vigorously for 1 minute, followed by storage on ice for 5 minutes. To separate 
the phases, samples were centrifuged at 13,000g for 30 minutes at 4°C. The aqueous 
phase was removed and transferred to fresh 1.5 ml tubes with added 0.5 ml isopropanol 
(Sigma) and 2 μl linear acrylamide (Sigma). Samples were stored at -80 ºC overnight to 
precipitate the RNA. Samples were thawed on ice and centrifuged at 13,000g for 30 
minutes at 4°C to pellet the RNA. Pellets were washed with 75% ethanol twice, allowed to 
air dry for 5 minutes, and then resuspended in 50 μl RNAse-free water (Fisher). RNA 
concentration was assessed using a Nanodrop spectrophotometer (Thermo Scientific).  
RNA-seq libraries were prepared as previously described (297). Briefly, ribosomal RNA 
was depleted using the MICROBExpress bacterial mRNA enrichment kit (Sigma). mRNA 
was then fragmented using the NEBNext Magnesium RNA Fragmentation module (NEB) 
with minor modifications. During the fragmentation step, samples were incubated at 4°C 
for two minutes. During the ethanol precipitation step, samples were incubated at -80°C 
overnight. Sequencing libraries were prepared using the NEB Library Preparation kit 
E7300. Libraries were then purified using the Qiagen QIAquick purification kit. To isolate 
libraries of the correct size, the NEB QC Check and Size Selection using 6% 
polyacylamide gel E7300 protocol was used with minor modifications. 10 μl of gel loading 
dye was added to 25 μl of each sample. A pre-cast 5% TBE gel was used (Bio-Rad), and 
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each sample was loaded in 1 well. During gel electrophoresis, the voltage was set to 65V 
to account for the thinner gel. Samples were eluted from the gel by rotating end-to-end for 
at least two hours at 37°C. Samples were never vortexed, only inverted. The concentration 
and purity of final libraries was assessed using the Qubit dsDNA HS assay kit (Thermo) 
and the High Sensitivity Bioanalyzer kit (Agilent).  
Proteomics mass spectrometry sample collection and preparation  
To mitigate batch effects, for the 3.3-hr and 25.3-hr doubling times, of which there were 
three samples each, samples were collected from two separate chemostat batches. Since 
there were only two samples analyzed at the 13.8-hr and 6.0-hr doubling times, these 
samples were collected on subsequent days from the same chemostat batch. For each 
individual sample, 5 ml of chemostat culture (OD600 = ~0.7) was collected on ice, followed 
immediately by centrifugation at 4ºC at 14,000g for 5 minutes. The supernatant was 
removed and cells were washed once in 1 ml of 4 ºC sterile PBS. Cells were pelleted 
again, supernatant removed, and cell pellets were stored at -80 ºC.  
Samples were processed for global proteome mass spectrometry analysis by the Georgia 
Institute of Technology’s Systems Mass Spectrometry Core Facility following previously 
described methods (298). Briefly, frozen cell pellets were lysed on ice with chilled urea 
lysis buffer. Extracted proteins were reduced, alkylated and sequentially digested with 
LysC for 2 hours and with trypsin overnight. Peptides were desalted by solid phase 
extraction (SPE) using SepPak cartridges and labeled with the TMT10plex isobaric labels 
(ThermoFisher Scientific). The TMT-labeled peptides were pooled and desalted again 
using the SepPak cartridges.  The peptide mixture was first separated by high pH reverse 
phase chromatography using a Beckman System Gold HPLC system with a Zorbax 300 
Extended C18 column (Agilent).  A total of 120 fractions were collected and pooled into 
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10 fractions as previously described (299).  Both the unfractionated and the 10 pooled 
fractions were analyzed by nano-LC/MS-MS using Dionex nanoLC system coupled to a Q 
Exactive Plus mass spectrometer (Thermo Scientific) as previously described (300) with 
the following modifications. Reverse phase chromatography was performed using an in-
house packed column (40 cm long X 75 μm ID X 360 OD, Dr. Maisch GmbH ReproSil-Pur 
120 C18-AQ 1.9 µm beads) and a 120 min. gradient.  MS settings included MS1 scans 
(70,000 resolution, 3 × 106 AGC, and 20 ms maximal ion time) and 12 data-dependent 
MS2 scans (35,000 resolution, 5 × 104 AGC, 120 ms maximal ion time, HCD, 30% 
normalized collision energy, 1.6 m/z isolation window with 0.3 m/z offset, and 20 s dynamic 
exclusion). 
RNA-seq bioinformatic analyses 
RNA-seq reads were trimmed using Cutadapt version 1.8.1 with default parameters and 
a minimum read length cut-off of 18 bases (301). Reads were then mapped to the current 
NCBI PA14 genome assembly (GCA_000014625.1 ASM1462v1) with Bowtie 2.2.3 using 
the default parameters (302). Gene counts were tallied to the coding sequences (CDS) 
using the R package Subread 2.0.0 with the strand specific option (-s 1) enabled (303) 
using the current GFF file downloaded from The Pseudomonas Genome Database (304).  
Proteomics mass spectrometry bioinformatics analyses 
Proteome Discoverer v2.1 (Thermo Fisher Scientific) and Mascot (Matrix Science) v2.6 
were used to process raw data files. Data was aligned with the Pseudomonas.com PA14 
proteome and the common repository of adventitious proteins (cRAP) v1.0. Protein 
identification allowed an MS tolerance of ± 10 ppm and an MS/MS tolerance of ± 0.8 Da 
ppm along with permission of up to 2 missed tryptic cleavages. Quantification was 
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achieved by calculating the sum of centroided reporter ions within a ± 2 millimass unit 
(mmu) window around the expected m/z for each of the four TMT reporter ions. 
All comparative analyses were performed with R (305). The R package MSnbase (306) 
was used for processing proteomics data. Briefly, this entailed missing value removal 
(instances where a protein was identified but not quantified in all channels were rejected 
from further analysis), log2-transformation of the raw data, followed by sample 
normalization; utilizing the 'diff.median' method in MSnbase. Protein differential 
abundance was evaluated using the Limma package (307). Differences in protein 
abundances were statistically determined using the Student's t‐test with variances 
moderated by Limma's empirical Bayes method. P-values were adjusted for multiple 
testing by the Benjamini Hochberg method (308). Proteins were considered as increased 
or decreased in abundance, only when their log2 fold change was >1 or <−1, respectively, 




CONCLUSIONS AND FUTURE DIRECTIONS 
1.20 The Role of Pseudomonas aeruginosa Glutathione Biosynthesis in Lung and 
Soft Tissue Infection  
1.20.1 Summary of results 
P. aeruginosa is a leading public health threat, particularly in immunocompromised people 
and in hospital settings (1, 10, 15). It is a versatile bacterium capable of infecting multiple 
body sites, including the skin and soft tissues. However, current antibiotic therapies are 
insufficient for treating these infections, necessitating a better understanding of P. 
aeruginosa infection biology. In this work, we focused on the role of GSH for P. aeruginosa 
during infection. GSH is a major cellular antioxidant that is involved in a variety of cellular 
processes, including protection from oxidative stress, toxins, and regulation of pH and 
osmolarity (206, 207). In vitro experiments have shown that GSH is involved in many 
different cellular processes that are important for infection, including motility, biofilm 
formation, toxin production, and quorum sensing (71, 155, 176, 214, 215). However, the 
role of GSH biosynthesis during mammalian infection, particularly in different sites of 
infection, was unclear.  
We found that GSH is critical for normal P. aeruginosa growth in vitro. P. aeruginosa 
ΔgshA grown in minimal media without GSH had a severe growth rate defect, but the 
growth rate was restored to WT levels with the addition of exogenous GSH (Figure 1). 
We speculate that the conflicting results in published literature regarding GSH-mediated 
phenotypes may be due to inadvertent use of media that contains GSH, such as LB broth. 
Using disc diffusion assays, we then showed that GSH biosynthesis provides P. 
aeruginosa with protection against some antimicrobials, including hydrogen peroxide, 
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bleach and ciprofloxacin (Table 1). Finally, we also studied the role of P. aeruginosa GSH 
biosynthesis in four mouse infection models: surgical wound, abscess, burn wound, and 
acute pneumonia. We discovered that P. aeruginosa ΔgshA was slightly less virulent in 
the acute pneumonia infection model but was equally virulent in the three other models 
(Figure 2, 3). Future directions building off of this work could 1) elucidate the role of GSH 
in regulating cellular pH and osmolarity in P. aeruginosa, 2) explore additional mouse 
models of infection, 3) test the efficacy of combination GSH inhibitor and antibiotic therapy 
in vivo, 4) elucidate the mechanism for why GSH biosynthesis provides P. aeruginosa a 
fitness benefit in the lungs and 5) explore the effect of exogenous GSH therapy on P. 
aeruginosa infection.  
1.20.2 Role of GSH biosynthesis for pH and osmolarity regulation in P. aeruginosa 
The ability to resist pH and osmotic stress is important for bacterial survival in the 
environment and in the host during infection. In some Gram-negative bacteria, GSH plays 
an important role in controlling intracellular osmolarity and pH by regulating the closing of 
K+ channels (206). E. coli with mutations in GSH biosynthesis genes, or in GSH-regulated 
K+ channel genes, leak K+ into the extracellular environment and cannot grow in low K+ 
media (213). Similarly, in Rhizobium tropici, GSH biosynthesis mutants are 
hypersusceptible to osmotic and acid shock (309). AMPs, a component of the innate 
immune system, create pores in bacterial membranes, causing leakage of cellular 
contents, osmotic shock, and death. In Yersinia enterocolitica (233), Neisseria 
meningitides (231), and Salmonella typhimurium (232) mutants in GSH biosynthesis or 
K+ transport are hypersusceptible to AMPs. However, to our knowledge, the role of GSH 
in protecting P. aeruginosa from pH or osmotic shock has not been explicitly tested.  
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Follow-up experiments, similar to those conducted in Figure 1, could test how pH or 
osmotic shock affect the growth rate of P. aeruginosa ΔgshA. Both WT and P. aeruginosa 
ΔgshA would be grown in MOPS-glucose, and the growth rate of the bacteria would be 
monitored over time using a spectrophotometer. To test the effect of osmotic stress, the 
bacteria could be grown in varying concentrations of K+. Likewise, to measure the effect 
of pH stress, the bacteria could be grown in MOPS minimal media adjusted to a range of 
different pH. To chemically complement the mutant, the bacteria would also be grown with 
or without exogenous GSH added to the medium. These growth rates would be compared 
to growth in normal MOPS-glucose, since P. aeruginosa ΔgshA already has a growth rate 
defect in MOPS-glucose. More in-depth procedures could also be used to measure 
intracellular K+ and pH levels in the ΔgshA mutant compared to the WT. Radiolabeled 
weak acids or fluorescent dyes have been used to measure intracellular pH (309, 310), 
while intracellular K+ levels could be quantified using flame photometry (213, 309).  
Results from these experiments would further elucidate the physiological role of GSH in 
P. aeruginosa. If we find that P. aeruginosa ΔgshA has a growth rate defect upon exposure 
to low pH, this may help explain why P. aeruginosa ΔgshA is severely attenuated for 
virulence in Drosophila (71) and C. elegans infection models (155). In these two models, 
P. aeruginosa colonizes the low pH environment of the gut. If we find that P. aeruginosa 
ΔgshA is resistant to osmotic stress, this may help explain why we observed P. aeruginosa 
ΔgshA resistance to AMPs (Table 1). Such a result may suggest that either GSH does not 
play a role in regulating osmotic stress upon exposure to AMPs, or there may exist 
additional redundant systems. Finally, if P. aeruginosa ΔgshA is found to be resistant to 
both osmotic and pH stress, that may also help explain why it was not severely attenuated 
in mice; mammalian blood is highly osmotic and oxidative (311), and bloodstream 
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dissemination is a key attribute of some infection types, including burn wound and acute 
pneumonia infections. 
1.20.3 Additional mouse models of infection 
We limited the number of mouse models that we investigated to four because of ethical 
considerations. Since P. aeruginosa ΔgshA was less fit in only one of the mouse models 
that we tested (acute pneumonia, Figure 3), it is unlikely that P. aeruginosa ΔgshA would 
be severely attenuated in a different mouse model of infection. However, if this work were 
investigated further, there are two more compelling mouse models to test: intraperitoneal 
(IP) and intravenous (IV) (179, 312, 313). Both are models of P. aeruginosa sepsis, which 
is a clinically relevant route of infection (174, 201). The IP model involves an injection of 
bacteria into the body cavity through the abdomen, while the IV model features 
administration of bacteria directly into the bloodstream through the tail vein. As mentioned 
previously, mammalian blood is hostile to bacterial growth because it is osmotic and 
oxidative, and it contains anti-bacterial components of the innate immune system such as 
complement and AMPs (311). GSH-deficient Yersinia pestis mutants display a severe 
growth defect in both whole defibrinated blood and in heat-treated serum (233). GSH 
biosynthesis mutants of Salmonella enterica were attenuated in an IP mouse model (218), 
and GSH-deficient Listeria monocytogenes mutants were attenuated in an IV mouse 
model (208).  
Results from testing P. aeruginosa ΔgshA mutants in either an IP or IV mouse model 
would more directly assess P. aeruginosa’s requirement for GSH biosynthesis in the 
blood. While bloodstream dissemination is characteristic of late stage burn wound and 
acute pneumonia P. aeruginosa infections, P. aeruginosa ΔgshA may have been able to 
acquire host GSH from the tissues before migrating to the bloodstream, which may have 
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helped it survive in the blood. In contrast, sepsis is the main clinical feature of IP and IV 
infections, and in the IV model, P. aeruginosa ΔgshA is subjected to the blood 
immediately. It would also be possible to test this hypothesis in vitro first. Similar to the 
experiments conducted in Figure 1, P. aeruginosa ΔgshA and WT could be grown in 
MOPS-glucose with added whole blood or serum, and their growth rate could be 
monitored over time. If the P. aeruginosa ΔgshA mutant demonstrates a growth rate defect 
in the presence of whole blood or individual blood components in vitro, then that evidence 
would suggest a role for GSH biosynthesis for P. aeruginosa in the blood.   
1.20.4 Combination GSH inhibitors and antibiotic therapy 
P. aeruginosa infections are notoriously difficult to treat due to P. aeruginosa’s high innate 
tolerance to antimicrobials. Therefore, new treatments are urgently needed (1, 66). As we 
demonstrated in Table 1, P. aeruginosa ΔgshA is hypersusceptible to the antibiotic 
ciprofloxacin. Future work could assess the potential of combination therapy using GSH 
inhibitors and ciprofloxacin together as a novel P. aeruginosa treatment strategy. This 
antibiotic is clinically relevant, as oral ciprofloxacin is widely used to treat a variety of 
human P. aeruginosa infections, including lung and soft tissue infections (314, 315). There 
is a precedent for this strategy; some experimental cancer therapies use GSH inhibitors 
in combination with chemotherapeutic agents (316, 317). Furthermore, we hypothesized 
that P. aeruginosa ΔgshA may have been able to scavenge GSH from the host in order to 
offset any GSH-related fitness defects. GSH inhibitors would deplete intracellular GSH 
levels from both P. aeruginosa and from the host, which may help sensitize P. aeruginosa 
to ciprofloxacin and to the immune system. However, since mammalian cells also require 
GSH (207), it would be necessary to find a balance between harming the bacteria while 
sparing the host.  
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First, we would determine whether GSH inhibitors can induce heightened ciprofloxacin 
susceptibility in WT P. aeruginosa in vitro. GSH inhibitors include buthionine sulfoximine 
(BSO) (223) or diethylmaletate (DEM) (235). Similar to the experiments conducted in 
Table 1, we could perform disc diffusion assays on MOPS-glucose + tryptone plates with 
WT P. aeruginosa and ciprofloxacin + GSH inhibitors, as well as treatment with 
ciprofloxacin alone and GSH inhibitors alone as controls. We would expect to see WT P. 
aeruginosa hypersusceptible to ciprofloxacin + GSH inhibitors, similar to P. aeruginosa 
ΔgshA treated with ciprofloxacin. Alternatively, WT P. aeruginosa could be pre-treated 
with GSH inhibitors before plating and ciprofloxacin exposure.  
Before testing in mice, we could then try an in vitro cell culture system (89, 136, 137). We 
could co-culture WT P. aeruginosa with lung epithelial cells (or other appropriate cell 
types) and treat them as before with ciprofloxacin + GSH inhibitors, ciprofloxacin alone, or 
GSH inhibitors alone. Here, we would determine which concentrations, if any, of 
ciprofloxacin + GSH inhibitors would be effective in killing P. aeruginosa without causing 
severe stress to the lung cells. We would also want to achieve a significantly higher P. 
aeruginosa killing in the ciprofloxacin + GSH inhibitors group compared to treatment with 
ciprofloxacin alone. P. aeruginosa viability would be assessed using serial dilution and 
plate counts. Lung cell health in treated vs. untreated cultures could be assessed by 
comparing lung cell viability, histology, ciliary beating, and transepithelial electrical 
resistance (TEER), which measures the integrity of the epithelial tight junctions (318).  
Since we know that P. aeruginosa ΔgshA is more susceptible to ciprofloxacin in vitro 
(Table 1), we next could examine whether P. aeruginosa ΔgshA is more susceptible than 
the WT to ciprofloxacin treatment in vivo. Because P. aeruginosa ΔgshA was modestly 
less fit than the WT in the acute pneumonia model (Figure 3), we would start these follow-
up experiments in the acute pneumonia model as well. Ciprofloxacin has previously been 
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used in this infection model (319, 320). We would infect mice with WT or P. aeruginosa 
ΔgshA as before, and either treat mice with ciprofloxacin or leave them untreated as a 
control. To assess the efficacy of the treatment, we would measure viable bacterial loads 
in the lungs over time and compare lung histology as a measure of lung damage. 
Histological indicators of lung damage include leukocyte infiltration, edema, blood clotting, 
and tissue necrosis. We would expect to see enhanced clearing of P. aeruginosa ΔgshA 
than the WT in the ciprofloxacin treated mice. A range of ciprofloxacin dosing 
concentrations may also be necessary to establish a dose-response curve. Alternatively, 
we could perform competition assays with WT or P. aeruginosa ΔgshA. We would infect 
mice with equal proportions of WT and P. aeruginosa ΔgshA, then either leave mice 
untreated or treat with ciprofloxacin. We could measure the final proportions of WT and P. 
aeruginosa ΔgshA using qPCR. We could expect the proportion of WT:ΔgshA to be 
significantly higher in the ciprofloxacin treated group compared to the control.  
Finally, we would test combination therapy of ciprofloxacin + GSH inhibitors in vivo. We 
would infect mice with WT P. aeruginosa and treat with ciprofloxacin alone, GSH inhibitors 
alone, and ciprofloxacin + GSH inhibitors. As before, we would measure bacterial loads in 
the lungs over time and assess lung histology. To check for host toxicity caused by GSH 
inhibitor treatment, we would also treat uninfected mice with GSH inhibitors + ciprofloxacin 
and then evaluate indicators of mouse health, such as  the presence of white spots on the 
liver (a sign of hepatocellular necrosis), and changes in body weight or behavior (scruffy 
fur, lethargy, rapid breathing, etc.) (257). If combination therapy with ciprofloxacin + GSH 
inhibitors is significantly more efficacious at killing P. aeruginosa in the mouse lung than 
ciprofloxacin alone, then these results would provide a first proof-of-concept of the 
potential benefit of the therapy. It may then be worth investigating further for its safety and 
efficacy in humans. However, this model has its limitations. A lack of toxicity in mice does 
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not always correlate with a lack of toxicity in humans (321). Furthermore, mice tend to 
metabolize drugs, including antibiotics, faster than humans, which can make it difficult to 
compare appropriate dosing (321).  
1.20.5 Mechanisms for GSH biosynthesis fitness benefit in the lung 
As demonstrated in Figure 3, P. aeruginosa ΔgshA was modestly less fit in the acute 
pneumonia mouse infection model, but it was as fit as the WT in the surgical wound, burn 
wound, and abscess models. It is not obvious why P. aeruginosa ΔgshA does not suffer 
from a significant fitness defect in these three models. For instance, oxidative stress is 
extensively involved in the pathophysiology of burns (see section 1.3.3). Immediately 
following a burn there is severe immune suppression, quickly followed by heightened 
inflammatory responses, activation of phagocytic cells, and subsequent production of 
ROS (34-36). Extracellular concentrations of GSH in the blood and soft tissues are 
normally low (250, 322), and tissue levels of GSH are further depleted by the increased 
oxidative activity (251, 323). Furthermore, work in our lab has previously shown that 
flagellar motility is a fitness requirement for P. aeruginosa in burn wound infections (4), as 
P. aeruginosa uses flagellar motility to invade the bloodstream and become septic, leading 
to shock and death. However, GSH deficiency inhibits flagellar motility (71, 176, 215). 
Increased inflammatory responses, oxidative stress and tissue GSH depletion are similarly 
characteristic of chronic wound infections (18, 19). Future work could be directed at 
investigating the mechanisms for why GSH provides a fitness benefit for P. aeruginosa in 
the lung, but not in the soft tissues. 
One explanation may be differences in the infection environment. Extracellular 
concentrations of GSH in the tissues are typically very low; however, Alveolar fluid 
contains unusually high concentrations of extracellular GSH as a protectant against the 
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relatively high oxygen tension and oxidative stress present in the lung (207, 322). Under 
aerobic conditions, pyocyanin, a redox-active phenazine secreted by P. aeruginosa (see 
section 1.5), directly oxidizes GSH and produces hydrogen peroxide, depleting available 
GSH in the process  (92, 93). Oxygen availability also affects pyocyanin production; P. 
aeruginosa PAO1 produces little pyocyanin under anaerobic conditions {Arai, 2011 #412}. 
While determining oxygen availability during infection, particularly at different sites of 
infection, is an area of active investigation and debate, it is likely that P. aeruginosa is 
exposed to more oxygen in the lung than in the soft tissues {Wessel, 2014 #405}{Stacy, 
2016 #67}. Therefore, under aerobic conditions in the lung, P. aeruginosa may be 
stimulated to produce more pyocyanin, which in turn can oxidize host GSH. This reaction 
would deplete the pool of available reduced GSH and also produce hydrogen peroxide as 
a byproduct. As shown in Table 1, P. aeruginosa ΔgshA is hypersensitive to oxidative 
stress, which would further hinder P. aeruginosa ΔgshA’s survival in the lung.  
To test this hypothesis, we could determine the degree of GSH scavenging in the lung 
compared to the soft tissues. We could make a double mutant in both GSH biosynthesis 
and GSH import. The genes involved in GSH import in P. aeruginosa are unclear, but 
there are homologs in other bacteria {Vergauwen, 2010 #413}{Pittman, 2005 #414}, and 
a genetic screen could be performed to identify the GSH importer genes. We would then 
infect mice with P. aeruginosa ΔgshA and GSH importer double mutants in all four mouse 
models of infection. If we discover that the double mutants are less fit in the soft tissues, 
then this would indicate that P. aeruginosa ΔgshA is able to scavenge host GSH and offset 
its GSH biosynthesis deficiency. Likewise, the degree of fitness loss for the double mutant 
in the lung would indicate the degree that P. aeruginosa ΔgshA was able to scavenge 
GSH from the lung. In other words, if we do not find a significant fitness defect for the 
double mutant compared to the single P. aeruginosa ΔgshA mutant in the lung, this would 
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indicate that host GSH was not available to P. aeruginosa ΔgshA in the lung, likely 
because it was depleted due to the action of pyocyanin.  
An alternative test to this hypothesis is to explore the effect of catalase on P. aeruginosa 
ΔgshA fitness. Catalase is an enzyme that breaks down hydrogen peroxide into oxygen 
and water. P. aeruginosa makes several catalases, including the major, constitutively 
expressed catalase produced by the katA gene (324). We would first test if overproduction 
of catalase would protect P. aeruginosa ΔgshA from hydrogen peroxide. We would create 
WT and P. aeruginosa ΔgshA katA overexpression strains carrying katA expression 
plasmids. As before in Table 1, we would perform hydrogen peroxide disc diffusion assays 
with WT::katA and ΔgshA::katA strains. We would expect to see P. aeruginosa WT::katA 
less susceptible to hydrogen peroxide than the parent WT, and to see P. aeruginosa 
ΔgshA::katA also having reduced susceptibility to hydrogen peroxide, similar to or even 
surpassing the parent WT. We would then test these strains in the acute pneumonia 
mouse model as before in Figure 3. We would record mouse survival, but could also go 
more in-depth and record bacterial CFUs in the lungs over time or compare lung histology. 
If hydrogen peroxide is killing P. aeruginosa ΔgshA, then we would expect P. aeruginosa 
ΔgshA::katA to be better protected from hydrogen peroxide and have lethality or bacterial 
loads restored to WT levels. It is important to test P. aeruginosa WT::katA as well, as it 
may be more fit than the parent WT during infection because it is better protected from 
the hydrogen peroxide produced by the immune system. Alternatively, we could infect 
mice with P. aeruginosa WT or ΔgshA and treat the mice with exogenous catalase. In this 
case, we would also expect catalase treatment to protect P. aeruginosa ΔgshA, restoring 
lethality or bacterial loads to WT levels. However, exogenous catalase treatment may also 
be protective for the host.  
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A second approach to testing this hypothesis is knocking out pyocyanin production. We 
could create a P. aeruginosa ΔgshA, ΔphzM double mutant, and a ΔphzM single mutant 
(95). The absence of pyocyanin production in the ΔphzM mutants would be confirmed in 
vitro (215). We would then infect mice with P. aeruginosa WT; ΔgshA; ΔgshA, ΔphzM; 
and ΔphzM. It is important to test the P. aeruginosa ΔphzM single mutant as a control, 
since pyocyanin is a virulence factor that is toxic to the host, and deleting it will likely 
reduce P. aeruginosa’s virulence (94, 96). If pyocyanin production is key to the P. 
aeruginosa ΔgshA fitness defect, then we would expect to see the P. aeruginosa ΔgshA, 
ΔphzM double mutant more fit than the ΔgshA single mutant. However, the fitness loss in 
the single P. aeruginosa ΔphzM mutant may be so severe that it overshadows any fitness 
gains in the P. aeruginosa ΔgshA, ΔphzM double mutant.  
One caveat to this hypothesis is that previous studies have shown that P. aeruginosa 
ΔgshA produces less pyocyanin than the WT in tryptic soy broth (215). However, it is not 
known if P. aeruginosa ΔgshA produces less pyocyanin in the lung during acute 
pneumonia infections. It is possible that P. aeruginosa ΔgshA is able to compensate for 
its inability to biosynthesize GSH by importing host GSH, which is available in alveolar 
fluid. Or, the reduced pyocyanin levels produced by P. aeruginosa ΔgshA may still be 
sufficient to generate a harmful amount of hydrogen peroxide. To address this concern, 
we could infect mice as in Figure 3 with P. aeruginosa WT, ΔgshA, or uninfected controls, 
and measure lung pyocyanin and hydrogen peroxide concentrations. We could measure 
pyocyanin in whole lung homogenates using a spectrophotometric test or high-pressure 
liquid chromatography (HPLC) (215, 325). Hydrogen peroxide could also be quantified 
using a spectrophotometric test on captured exhaled breath (326, 327). As a control, we 
would expect to find higher pyocyanin and hydrogen peroxide levels in P. aeruginosa WT 
infected mice than uninfected mice. We may find that P. aeruginosa ΔgshA produces 
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pyocyanin and induces hydrogen peroxide stress at similar levels as the WT, supporting 
the hypothesis. However, if both pyocyanin and hydrogen peroxide levels are significantly 
lower in P. aeruginosa ΔgshA infected mice compared to P. aeruginosa WT infected mice, 
then those results would weaken support for this hypothesis.  
A second hypothesis for why P. aeruginosa requires GSH for fitness in the lung, but not 
in the soft tissues, is that GSH may modulate virulence factors that are more important for 
fitness in the lung. The requirement of T3SS for virulence in the mouse lung is well 
documented (64, 102, 178). The T3SS (see section 1.5) enables P. aeruginosa to inject 
host cells with toxins. These toxins can disrupt the lung epithelial barrier, allowing the 
bacteria to invade the bloodstream and become septic (64). Importantly, GSH-deficient P. 
aeruginosa mutants have reduced T3SS expression (176). While T3SS appears strongly 
correlated with virulence in the lung, its importance in the soft tissues is less well 
understood, and the fitness benefit of T3SS in these different sites of infection hasn’t been 
compared directly. In our previous Tn-seq study, we observed increased T3SS expression 
and lower T3SS mutant abundance in burn and surgical wound mouse models compared 
to growth in MOPS-succinate (4). A recent study showed that a T3SS and alginate double 
mutant had significantly lower bacterial loads in a rabbit ear model, however, single T3SS 
mutants weren’t tested (328). T3SS mutants were also less fit in a mouse abscess model 
of infection (173).  
To test this hypothesis, we would use all four mouse models (acute pneumonia, burn 
wound, surgical wound, and abscess) and infect mice with either P. aeruginosa WT or a 
T3SS mutant (for example, ΔpcrV) (178). We would then compare bacterial loads between 
each site of infection. If T3SS is more important for fitness in the lung compared to the soft 
tissues, then we would expect the difference in bacterial loads for P. aeruginosa WT 
compared to P. aeruginosa ΔpcrV to be more severe in the lung than in the soft tissues. 
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However, if this hypothesis is incorrect and T3SS isn’t especially more important in the 
lung, then these studies would still better elucidate the role of T3SS for virulence in 
different sites of infection.  
1.20.6 Effect of exogenous GSH therapy on P. aeruginosa infection 
Excessive oxidative stress is a component of many different human pathologies, including 
chronic wounds (246), burn wounds (34), pneumonia (245, 247) and cystic fibrosis (329, 
330). Because of its robust antioxidant abilities, low toxicity and low cost, exogenous GSH 
therapy may be an attractive treatment option (207). Rodent experiments and human 
clinical trials have demonstrated that exogenous GSH treatment can significantly improve 
healing, reduce tissue damage, and lower mortality in chronic wounds (248, 249), burn 
wounds (35, 250, 251), and pneumonia (252-254). However, laboratory experiments 
regarding the effect of GSH therapy on injured tissue are usually conducted with 
uninfected tissue, so it is unknown how exogenous therapy may affect P. aeruginosa 
physiology and influence the severity of infection. Our data in Table 1 show that adding 
GSH to WT P. aeruginosa reduced its susceptibility to bleach and carbenicillin. Previous 
studies have also shown that P. aeruginosa WT exposed to exogenous GSH induced 
increased T3SS expression (176) and altered susceptibility to some antibiotics (217). 
Therefore, while exogenous GSH therapy may be beneficial for host cells, it may 
simultaneously promote unwanted P. aeruginosa phenotypes and potentially exacerbate 
infection. Therefore, further studies may attempt to elucidate the safety and efficacy of 
GSH administration in different types of P. aeruginosa infection. 
To test this hypothesis, we could repeat our four mouse infection models (surgical wound, 
burn wound, abscess, and pneumonia) with P. aeruginosa WT or uninfected controls, and 
then treat mice with GSH or leave untreated as a control. We could measure host health 
 84 
outcomes, such as survival (burn and pneumonia), histology, wound size (burn and 
chronic wound), and mouse physiological parameters (weight change, behavior). We 
would also measure P. aeruginosa bacterial loads over time as an indicator of the effect 
of exogenous GSH on P. aeruginosa survival. We may find that GSH treated groups have 
improved health outcomes compared to untreated groups, regardless of P. aeruginosa 
infection, which would indicate safety and efficacy of the treatment. Or, we may find that 
P. aeruginosa survives better in GSH treated animals, which may negate or even worsen 
any beneficial effect that exogenous GSH treatment may have. In that case, human clinical 
trials using exogenous GSH therapy should examine presence or absence of P. 
aeruginosa as a factor that could influence treatment outcomes.  
In conclusion, results from these future directions may further our understanding of the 
role of GSH in P. aeruginosa physiology, and may inform future treatment strategies.  
1.21 Transcriptomic and Proteomic Signatures of Growth Rate in Pseudomonas 
aeruginosa Grown in Chemostats  
1.21.1 Summary of results 
Bacteria use many complex, interconnected systems for adjusting their growth rate to suit 
their environmental conditions. The growth rate, or doubling time, has significant impacts 
on cellular physiology, from cell size, to ribosomal abundance, to stress tolerance, to 
antibiotic resistance (258, 267, 268). A few studies have provided insight into the range of 
doubling times that P. aeruginosa likely grows at during infection, and these growth rates 
are likely slower than the rapid logarithmic phase growth usually studied under laboratory 
conditions (262, 271-273). Because growth rate affects so many aspects of cellular 
physiology, better understanding the effect of growth rate will improve interpretations of 
RNA-seq data.  
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We used a chemostat, which allows the cellular density and growth rate to be precisely 
controlled while keeping other environmental factors near-constant (282-285). We 
cultured P. aeruginosa strain PA14 in MOPs succinate minimal medium at a wide range 
of four different doubling times, and mRNA and protein abundances were quantified using 
RNA-seq and proteomics mass spectrometry, respectively. We found that there are 
differing relationships between growth rate, mRNA expression, protein expression, and 
protein-to-mRNA ratios. There is a modest correlation between mRNA and protein levels, 
and these vary slightly with growth rate (Figure 7 and 8). We also observed greater 
variation in mRNA expression compared to protein expression. The variation in mRNA 
expression across growth rates is strongly correlated with the variance in protein-to-mRNA 
ratios across growth rates (Figure 5, Figure 12), while mean protein expression is strongly 
correlated with the protein-to-mRNA ratio (Figure 9).  
These results show that the assumption of a 1:1 correlation between mRNA and protein 
is not accurate for interpreting RNA-seq data. Instead, it may be feasible to apply a 
“conversion factor”, based on the protein-to-mRNA ratio for each gene. We have 
characterized conversion factors for roughly 3900 P. aeruginosa genes. Over half of these 
are stable across growth rates (Figure 11). However, the reliability of our conversion 
factors is limited by our use of only one strain and type of media. These conversion factors 
could be further refined by including different strains, media conditions, and even bacterial 
species.  
1.21.2 Building a computational model for predicting growth rate in human infection 
While RNA-seq is a powerful tool for profiling a “snapshot” of global gene expression, and 
it is one of a few techniques that can be used on bacteria sampled from human infections, 
is has limitations. When interpreting RNA-seq data, relative differences in gene expression 
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levels in the condition of interest are compared to those of in vitro conditions. However, 
environmental conditions often impact multiple genetic pathways simultaneously, making 
it difficult to discern the importance of individual physiological functions from changes in 
gene expression. Furthermore, because these comparisons are relative, it is difficult to 
draw conclusions about absolute qualities of the infection environment itself. For example, 
we currently cannot determine important characteristics such as bacterial growth rate, 
density, oxygen availability, or nutrient availability at the site of infection from RNA-seq 
data alone. In our laboratory, future directions for this work are aimed at 1) expanding the 
dataset to include a greater variety of experimental conditions, and then 2) building a 
computational model for predicting bacterial growth rate during human infection.  
1.21.2.1 Expanding the dataset with respect to media composition, strain, and species 
Here we presented a benchmark dataset of carefully controlled chemostat conditions that 
included four different generation times, one type of media, and a single strain of P. 
aeruginosa. Naturally, this dataset can be expanded in many different directions with 
regards to media composition, strain, and even species. These additional factors are all 
complementary and can build upon each other. Ultimately, expanding our dataset in this 
way will help better define a conserved, core set of genes that are differentially expressed 
with growth rate independent of other factors. It will also be a powerful dataset to use as 
an in vitro comparison in other RNA-seq experiments. Finally, this information will also 
further our understanding of basic bacterial physiology at the transcriptional level.    
We started with MOPS-succinate minimal media because P. aeruginosa succinate 
metabolism is relatively simple, well characterized, and reproducible (4, 221, 286). 
However, since gene expression is highly impacted by nutrient availability (276, 295, 296), 
future experiments using different types of media would allow us to more precisely identify 
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the genes that are differentially expressed with growth rate, independent of the limiting 
nutrient. It would also allow us to explore the interactions between other metabolic 
pathways and growth rate. One approach is to change the nature of the limiting nutrient, 
such as carbon, nitrogen, or phosphorus limitation (276, 295). A different approach is to 
use complex media such as diluted brain heart infusion broth (BHI) or SCFM. BHI is an 
animal-protein-based rich undefined laboratory media, while SCFM (as described in 
section 1.7.1) is designed to mimic human CF sputum. Importantly, these media types, 
particularly SCFM, more closely resemble the nutritional environment of the host during 
infection. We also know from previous in vitro work that the P. aeruginosa transcriptional 
profile in BHI or SCFM is very different than in minimal medium (43, 286).   
In these experiments we used only P. aeruginosa strain PA14, which is a widely used 
clinical strain isolated from a human chronic wound. However, natural human infections 
are usually composed of a mixture of strains (51, 331). While our previous work has shown 
that mRNA-to-protein ratios for a given gene are largely conserved between strains (in 
that case, P. aeruginosa PAO1 and PA14), differences between strains can cause 
variations in clinically relevant phenotypes, such as antibiotic resistance (292). For these 
reasons, our future directions include repeating these experiments with different strains of 
P. aeruginosa, such as PAO1, the most well-characterized laboratory strain, or PAB1, a 
CF human clinical isolate. We could directly compare responses in these strains to PA14 
by growing them in the same media, MOPS-succinate. We could also provide a potentially 
dramatically different transcriptional profile by growing them in diluted BHI or SCFM.  
As described in section 1.3, some infection types, such as chronic wounds and CF lung 
infections, are composed of polymicrobial communities, rather than a single species. 
Furthermore, it is probable that many genetic pathways with expression levels dependant 
on growth rate are conserved across living organisms, similar to how mechanisms of 
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general stress response are highly conserved (260, 276). While the focus of this work was 
on P. aeruginosa, our laboratory is interested in expanding this dataset to include two 
other clinically relevant bacteria: Mycobacterium abscessus (MAB) and Aggregatibacter 
actinomycetemcomitans. A. actinomycetemcomitans is a Gram-negative, facultative 
anaerobe that is associated with aggressive periodontitis (332, 333). One major 
advantage of studying oral pathogens is that it is relatively easy to collect human clinical 
samples. Mycobacterium abscessus is part of the Mycobacterium abscessus complex 
(MAB), a group of rapid growing, multi-drug resistant nontuberculous mycobacteria (NTM) 
known to commonly infect CF patients (334, 335). As before, we would culture these 
bacterial species in precisely controlled chemostat conditions. We plan to grow two clinical 
CF strains of Mycobacterium abscessus in SCFM, and one strain of A. 
actinomycetemcomitans in diluted BHI and in CDM (described in section 2.2). This 
information will allow us to identify genes that are differentially expressed in response to 
growth rate that are conserved across bacterial species.   
1.21.2.2 Building a computational model for predicting growth rate in human infection 
Performing RNA-seq on bacteria sampled directly from humans has the potential to reveal 
information about bacterial physiology during human infection without relying on 
laboratory models that may not recapitulate all aspects of a human infection. However, 
until recently, human sample RNA-seq has rarely been done due to technical challenges. 
The amount of bacterial RNA relative to human RNA is often very low, and the throughput 
and cost of sequencing technologies were prohibitive. Previous studies mainly used 
samples that were relatively easy to obtain and contained a greater proportion of bacterial 
RNA to host RNA, such as human stool or urine (288-290). Our laboratory has recently 
developed an RNA-seq protocol applicable for a diverse range of human samples, 
including expectorated CF sputum and chronic wounds (286, 287). Using this protocol to 
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continue to expand the number and diversity of human infection RNA-seq samples will 
greatly improve our knowledge of bacterial physiology during infection. However, while 
standard differential expression analysis allows us to identify which genes are expressed 
differently between in vitro and human samples, it can be difficult to interpret how these 
transcriptional differences relate to the bacterium’s infection environment and complex 
physiological functions. 
One method to address these shortcomings is flux-balance analysis (FBA) (336). FBA 
uses precise metabolic network reconstructions to mathematically calculate the flow of 
metabolites through a system and predict cellular behavior, such as oxygen consumption 
or growth rate. However, FBA is only as accurate as the underlying metabolic models, and 
thus can only be used to predict a small set of highly characterized phenotypes. A second, 
more common approach is the use of biomarker genes. Expression of a biomarker gene 
is directly linked to an environmental variable (337). For example, we have used 
expression of the biomarker gene cbb3-2 to indicate low oxygen availability (< ~2%) in P. 
aeruginosa aggregates (338). However, biomarker genes are not precisely quantitative, 
and might only be accurate for classifying environmental qualities into binary categories, 
such as presence/absence, or low/high availability of an environmental factor. Their use 
is also restricted to simple and well-characterized variables; they may not be accurate for 
features that are influenced by many complex variables simultaneously, such as growth 
rate.   
Future work in our laboratory aims to build a machine learning framework to quantify 
bacterial growth rate directly from gene expression data. This framework is based on a 
recently developed method used in Saccharomyces cerevisiae (339). In that work, 
researchers successfully built a computational model based on a small number of genes 
to accurately predict the growth rate of S. cerevisiae, Saccharomyces bayanus and 
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Schizosaccharomyces pombe, in different media conditions. Similarly, we will use our 
chemostat gene expression data to fit a multivariable LASSO (least absolute shrinkage 
and selection operator) regression model (340). LASSO regression analysis uses both 
feature selection and regularization in order to penalize solutions that require many 
features (genes) in order to avoid overfitting and improve prediction accuracy and 
interpretability. A regression analysis aims to model the relationship between a dependant 
variable and one or more independent variables, in this case to predict growth rate from 
gene expression data. Overfitting occurs when a model is not generalizable to other 
datasets. We want our model to be robust and avoid overfitting, since human sample RNA-
seq involves many different complex factors, for example host comorbidities, presence of 
co-infecting microbes, antibiotic treatment, etc. Feature selection is the process of 
narrowing down the number of genes to include in the model. Regularization shrinks the 
coefficient estimates towards zero, penalizing complex models with many features. These 
processes help build an accurate model with the minimal number of genes possible, since 
too many genes can cause overfitting.  
To develop and test our model, we will expand our current dataset with a wide variety of 
carefully controlled chemostat conditions that vary with respect to media, strain, and 
species, as described in the previous section. The key to establishing a precise 
relationship between variables like growth rate and media composition to gene expression 
is to specifically vary one variable at a time, so that any transcriptional changes observed 
can be attributed to that perturbation. Therefore, we could include samples with only one 
variable altered compared to our original dataset, such as P. aeruginosa strain PA14 
grown in SCFM, or strain PAB1 grown in MOPS-succinate. Furthermore, in order to 
validate our model, we also want to include samples with dramatically different 
transcriptional profiles, such as M. abscessus grown in SCFM. Taken together, we will be 
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able to determine a core set of genes with expression dependent on growth rate 
independent of other factors.  
We will test the accuracy and robustness of our model for predicting bacterial growth rate 
from RNA-seq data using k-fold cross validation and bootstrap randomization. k-fold cross 
validation involves repeatedly randomly dividing the dataset into new test or training 
samples, training the model on the new training samples, and assessing how accurately 
it predicts the new test samples. Bootstrap randomization involves randomly shuffling the 
dataset and re-running the LASSO algorithm to obtain pseudo p-values. After assessing 
model accuracy using chemostat data, we will then validate the model using RNA-seq 
data previously generated in our lab where the generation time of P. aeruginosa is known. 
We will then use our model to estimate P. aeruginosa growth rate from animal models and 
human infection samples.  
Should LASSO not perform well, elastic net may be used as an alternative. Elastic net is 
also a regularized regression model, but it adds ridge regression into the feature 
penalization function, which may be helpful for dealing with many genes with similar 
patterns of gene expression. However, if our model is still not capable to accurately 
quantifying growth rate from human samples, it is likely that we will at least be able to 
classify growth rate into arbitrary categories, such as slow, medium, or fast growth.  
In conclusion, completion of these future directions will result in both a large, carefully 
controlled dataset of bacterial transcriptional profiles, and a robust computational 
framework for predicting P. aeruginosa growth rate during human infection. Since growth 
rate impacts many aspects of cellular physiology, particularly antibiotic resistance, this 
information will improve our understanding of fundamental cell biology and may inform 
future treatment strategies.   
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1.22 Final discussion 
In conclusion, this research has elucidated fundamental aspects of P. aeruginosa 
physiology. We assessed the role of GSH biosynthesis for P. aeruginosa during infection, 
and found that it confers a modest fitness benefit in the lung, but not in the soft tissues. 
We also explored how growth rate impacts P. aeruginosa mRNA and protein expression, 
and identified conversion factors that could be used to more accurately predict protein 
abundance from RNA-seq data. However, many questions remain unknown, and this work 
could be further refined. Follow-up studies could provide insight into the mechanism of 
GSH biosynthesis in the lung and determine the safety and efficacy of combination therapy 
with GSH biosynthesis inhibitors and antibiotics. Likewise, our conversion factors could 
be made more robust and accurate by expanding our dataset with respect to strain, media 
composition, and even bacterial species. The research presented in this dissertation is 
one small contribution to the global effort to better understand, and ultimately treat, P. 
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